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Summary 
 
The malaria parasite, Plasmodium falciparum, has become increasingly resistant to all commercially 
available drugs used in the treatment of malaria, and as such, the development of new antimalarial 
drugs with novel targets is of great importance. The coenzyme A (CoA) biosynthesis pathway is one 
such novel target since CoA and its precursor, pantothenate, have been shown to be essential for 
organism survival.  
 
N-phenethyl-α-methyl pantothenamide, a pantothenate analogue, has been shown in a previous 
study to inhibit growth in both bacteria and Plasmodium parasites, however the mode of action of 
this pantothenamide in Plasmodium is still unknown, and was thus investigated in this study. 
 
First, Plasmodiums’ requirement for pantothenate was investigated. We determined that parasites 
could survive without an extracellular source of pantothenate for up to eight days, however this 
contradicted what was found in literature, and was likely to be due to a Mycoplasma infection found 
late in the study. Secondly, it was investigated whether N-phenethyl-α-methyl pantothenamide can 
be metabolized to its CoA antimetabolites by the CoA biosynthetic enzymes present in P. falciparum. 
This was done by investigating the metabolism of the compound in both cell lysates and in in vivo P. 
falciparum cell cultures and it was found that PfPanK and PfDPCK is active in parasite lysates, while 
PfPPAT is inactive in parasite lysates. We could therefore not determine if the pantothenamide under 
investigation is being metabolized in the parasite by using lysates, but this is the first demonstration 
of the activity of PfDPCK in parasites lysate. Finally, we wanted to investigate the effect of tricyclic 
methylthiophenyl propanamide (TMP), a non-pantothenate analogue that inhibits the CoA 
biosynthesis pathway in other organisms, on P. falciparum proliferation. TMP was synthesized to 
use as a tool to investigate the mechanism of action of N-phenethyl-α-methyl pantothenamide to 
support that pantothenamides do not inhibit pantothenate kinase, as is known for TMP, but are rather 
metabolized downstream in the pathway. TMP was successfully synthesized and purified, however 
yields were too low to test TMP as an inhibitor of P. falciparum proliferation. 
 
Not only did the work done in this study shed more light on the mode of action of pantothenamides 
in P. falciparum, but also gave valuable insight into parasite biochemistry.  
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Opsomming 
 
Die malaria parasite, Plasmodium falciparum, het tot dus ver weerstand opgebou teen alle 
kommersiële beskikbare middele vir die behandeling van malaria. Die ontwikkelling van nuwe 
middele teen malaria wat ‘n uitwerking het op nuwe teikens in the parasite is van die uiterste belang. 
Die koënsiem A (KoA) biosintese padweg is een so 'n spesifieke teiken, aangesien KoA en sy 
voorloper, pantoteensuur, essensieël is vir die organisme se oorlewing. 
 
N-fenetiel-α-metiel-pantoteenamied, ‘n pantoteensuur-analoog wat reeds in vorige studies inhibisie 
van bakteriële- en Plasmodium parasiet-groei tot gevolg gehad het is in hierdie studie ondersoek. 
Meer spesifiek, die metode van werking van hierdie pantoteenamied, wat tans nog onbekend is, was 
die fokus gedurende die betrokke studie. 
 
Eerstens het ons P. falciparum se pantoteensuur vereistes ondersoek. Ons het bepaal dat die 
parasiete tot en met agt dae kan oorleef sonder 'n ekstrasellulêre bron van pantoteensuur, maar dit 
is teenstrydig met wat ons in die literatuur vind, en is waarskynlik as gevolg van ‘n Mikoplasma 
infeksie wat ons eers laat in die studie ontdek het. Tweendens het ons bepaal of N-fenetiel-α-metiel-
pantoteenamied omgesit word na die ooreenstemmende KoA-antimetaboliete deur die ensieme van 
die KoA biosintese padweg teenwoordig in P. falciparum. Die bepaling is gedoen deur die aktiwiteit 
van die ensieme te ondersoek in beide sellisaat en in in vivo P. falciparum selkulture. Daar is bevind 
dat PfPanK en PfDPCK in parasiet sellisaat aktief is, terwyl PfPPAT onaktief is. Ons kon dus nie 
bepaal of die pantoteenamied wat ons ondersoek deur die parasiet lisaat gemetaboliseer word nie, 
maar dit was die eerste bewyse van PfDPCK in parasiet sellisaat. Laastens, is die effek van trisikliese 
metieltiofeniel-propaanamied (TMP), 'n nie-pantoteensuur analoog wat die KoA biosintese padweg 
inhibeer in ander organismes, ondersoek as inhibitor van P. falciparum. TMP is gesintetiseer ter 
ondersteuning van die meganisme van aksie van N-fenetiel-α-metiel-pantoteenamied. Spesifiek wou 
ons toon dat the pantoteenamiede nie pantoteensuurkinase inhibeer soos TMP nie, maar eerder 
verder af in die padweg gemetaboliseer word. Die sintese en suiwering van TMP was suksesvol, 
maar die opbrengs was te laag om TMP te toets as ‘n inhibitor van P. Falciparum groei. 
 
Hierdie studie sal meer lig werp op die metode van werking wat van toepassing is op 
pantoteenamiede en meer inligting verskaf omtrent die biochemie van die parasite. 
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Chapter 1: Coenzyme A biosynthesis as an 
antiplasmodial drug target 
 
1.1 Cause and Effect of Malaria as a Disease 
Malaria is a disease that is caused by a parasitic, single celled organism from the genus Plasmodium. 
Of the approximately 250 known species of Plasmodium, five of these species are able to infect 
humans, namely P. falciparum, P. vivax, P. malariae, P. ovale, and the most recently discovered P. 
knowlesi [1].  
 
Globally, in 2015, it is estimated that 2.1 billion people were at risk of contracting malaria, with 
approximately 214 million new cases leading to around 438 000 deaths. Although these numbers 
have decreased drastically over the last 15 years, malaria remains a worldwide problem [1]. P. vivax 
and P. falciparum are two of human malaria parasites that are of high interest. While P. vivax is more 
widely spread than P. falciparum and is responsible for most infections and many deaths outside of 
the African continent, it often has a dormant liver stage that can last for months, or occasionally 
years, before its symptoms present. P. falciparum, however, is rampant in Africa and is the greatest 
contributor to deaths caused by malaria, with approximately 90% of malaria-related deaths occurring 
in Africa [1]. In Sub-Saharan Africa, the individuals most affected by malaria and contributing most 
to the malaria death toll are pregnant women and children under the age of 5, however in areas with 
major health burdens, attempts to decrease malaria-related mortalities are also a challenge [1]. 
 
Plasmodium parasites usually have three main life stages of which the first one occurs in mosquitoes 
and the last two stages (i.e. liver and blood-stages) occur in humans (Figure 1.1). The female 
Anopheles mosquito is the vector that causes the spread of this deadly disease and forms the first 
part of the parasite life cycle; during a blood meal, the mosquito takes up the blood of an infected 
individual, containing parasites known as gametocytes, and then becomes a carrier of the parasite. 
Parasites can be taken up as male (microgametocytes) and female (macrogametocytes) 
gametocytes inside the mosquito where they undergo sexual reproduction in the sporogonic cycle, 
to ultimately mature into sporozoites that are then injected into another individual during the 
mosquitos’ next blood meal [2]. Once a human is infected, the malaria parasite first goes through a 
liver stage, otherwise known as the hepatic stage, where they replicate inside the liver cells and 
further mature into millions of merozoites. These merozoites are then released into the blood stream 
where they invade the red blood cells – also known as the erythrocytic stage. It is during this stage 
that the symptoms, such as fever, diarrhea, headaches and nausea, are present [2, 3]. During the 
erythrocytic stage some parasites can differentiate into male and female gametocytes that are then 
again ingested by an Anopheles mosquito during a blood meal to complete the parasite life cycle [3]. 
Stellenbosch University  https://scholar.sun.ac.za
2 
 
 
 
Figure 1.1: The life cycle of a malaria parasite, such as P. falciparum , going through 
mosquito stage, hepatic stage and erythrocytic stage. See text for details. (Reproduced 
with permission from [3], Copyright Massachusetts Medical Society.)  
 
1.2 Efforts to Control and Treat Malaria 
The World Health Organization (WHO) has set out strategies to combat malaria to decrease the 
number of annual malaria cases and to lower malaria-related mortality. The newest strategy set out 
Stellenbosch University  https://scholar.sun.ac.za
3 
 
by the WHO for 2016-2030, called the Global Technical Strategy for Malaria, attempts to decrease 
malaria incidences and mortality by 90%, with the first milestone aimed at a 40% decrease by 2020. 
This is to be achieved by making sure that those at risk have access to preventative measures, 
diagnosis and treatment, and to increase funding available for the control and elimination of malaria 
[1].  
The attempts to combat malaria occur predominantly in two ways: the first is focused on minimizing 
contact between mosquitoes, the parasite carriers, and humans, while the second is focused on 
using drugs to prevent or cure malaria once infection has taken place. However, adding to the 
difficulty of controlling the spread of malaria is the issue of resistance; not only are mosquitoes 
becoming increasingly resistant to insecticides, but certain strains of the malaria parasite itself are 
resistant to all current forms of drug-based treatment [1, 4]. 
 
1.2.1 Insecticides 
The efforts made to minimize human contact with mosquitoes (vector control) include the widespread 
distribution of bed nets and clothing treated with insecticides, window screens and insect repellents, 
as well as spraying interior wall cavities of homes with insecticides. In addition to this, efforts are 
being made to control the breeding of the Anopheles mosquito in an attempt to limit the spread of 
the disease [1].  
Although insecticides, such as organochlorine, organophosphate, carbamate and pyrethroid have 
thus far aided in controlling the spread of malaria by controlling the mosquito population, the 
insecticides are becoming less effective as Anopheles mosquitoes are developing resistance 
towards them. Approximately 77% of monitored countries have reported noted resistance to at least 
one type of insecticide and 63% of the monitored countries noted resistance to more than one 
insecticide over the last 6 years. An example of this resistance is towards the insecticide pyrethroid 
which was reported in 2014 by 75% of the monitored countries to no longer be effective [1]. 
 
1.2.2 Drugs and Treatment 
Where prophylaxis and treatment of the disease are concerned, efforts are being made on various 
fronts to achieve malaria eradication world-wide. The development of a recombinant P. falciparum 
vaccine against malaria has recently been achieved; however, this vaccine is currently in stage III of 
clinical trials and not yet commercially available [1]. The vaccine, named RTS,S/AS0, was used in a 
4-year pilot study in Africa on children between the ages of 5-18 months during which it was 
administered in 4 doses over a period of 20 months. It was found to be 39% effective against clinical 
malaria, and 31.5% effective against severe cases of malaria. Further tests are however still being 
conducted [1]. 
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Although vaccines are an excellent strategy in the prevention of the disease, the limited success of 
RTS,S/AS0 clearly supports the ongoing desperate need for the development of new antimalarial 
drugs. Over the years, many effective drugs have been used to combat malaria, however malaria 
parasites are showing marked resistance against them, with certain strains of P. falciparum currently 
showing resistance to all known drugs [1, 4]. An example of this resistance is against the well-known 
antimalarial, chloroquine. Chloroquine was used mostly during the 1940s and 1950s, however 
resistance to chloroquine started to develop presenting in Africa around the 1970s causing an 
increased spread of malaria [1]. Chloroquine-resistance in P. vivax has been confirmed in multiple 
countries, including Brazil and Thailand [1]. 
After resistance to chloroquine became prevalent, treatment with drugs such as sulphadoxine-
pyrimethamine, mefloquine and quinine became common [4]. However, with resistance building up 
against all these drugs, artemisinin-based combination therapies were adopted as a first line of 
treatment, and were shown to be effective against P. falciparum and P. vivax. When used as a 
monotherapy, there is a high rate of treatment failure because of the short half-life of artemisinin and 
its derivatives, however, when used in combination therapies with mefloquine, lumefatrine, 
amodiaquinem, piperaquine or pyronaridine (compounds with longer half-lives), there was a 
prolonged antimalarial pressure, increasing the efficacy of artemisinins and reducing the risk of 
developing resistance [5, 6]. Recently, P. falciparum has been found to start showing resistance 
towards artemisinins in some countries such as Thailand and Cambodia [1], however treatment 
failure in Africa is still less than 10% for the artemisinin, artesunate-amodiaquine, which is used as 
a first or second-line treatment. 
 
With the two Plasmodium strains that are the greatest contributors to mortality caused by malaria 
showing increasing resistance to known forms of treatment, the development of novel drugs targeting 
new biochemical pathways or processes in the parasite is becoming a necessity.  
 
1.3 Essential Nutrients for Malaria Survival 
Several in vitro studies have been done to ascertain vitamin and amino acid requirement in different 
species of Plasmodium to determine which of these nutrients are essential for the survival and 
proliferation of these parasites. It was shown that the core nutrients needed for the survival of P. 
falciparum in vitro are the amino acids isoleucine, cysteine, glutamate, glutamine, proline, tyrosine 
and methionine, as well as nutrients pyridoxine, glutathione, potassium chloride, sodium chloride, 
disodium phosphate, calcium nitrate, magnesium sulfate, glucose, folic acid, riboflavin, 
hypoxanthine, p-aminobenzoic acid (PABA), biotin, human serum and pantothenate [7]. 
Stellenbosch University  https://scholar.sun.ac.za
5 
 
 
Figure 1.2: The chemical structures of vitamins (biotin, thiamine and pantothenate) 
essential for parasite survival.  
 
Biotin (vitamin B7, Figure 1.2) is generally biosynthesized in bacteria and plants but cannot be 
biosynthesized in humans, thus the uptake of biotin in humans is solely through diet. Like humans, 
Plasmodium parasites are unable to biosynthesize this vitamin, yet possess the acetyl-coenzyme A 
carboxylase enzyme [8]. Acetyl-coenzyme A carboxylase is a biotin-dependent enzyme to which 
biotin is covalently attached by the enzyme biotin-protein ligase. Trager showed that when chickens 
infected with Plasmodium were fed a biotin-deficient diet, the parasitemia in the erythrocyte stage 
were almost half of that found in chickens that were fed a diet supplemented with biotin, highlighting 
the parasites’ requirement for biotin [9].  
The role of thiamine (vitamin B1, Figure 1.2) in parasite proliferation has been investigated recently 
[10]. This vitamin was originally not believed to be essential for parasite survival, however it was 
shown that complete depletion of thiamine from erythrocytes is detrimental to parasite growth. 
Plasmodium parasites are capable of thiamine synthesis, however it seems as if the demand in the 
parasite for thiamine is higher than production, therefore thiamine is also sourced from the host [10, 
11]. 
Pantothenate (vitamin B5 or pantothenic acid in its non-ionized form) cannot be biosynthesized by 
Plasmodium parasites (Figure 1.2) de novo. This was discovered in 1946 by Brackett et al., who 
studied avian malaria parasites, and found that when chickens infected with Plasmodium 
gallinaceum were fed a diet that lacked pantothenate, the blood pantothenate levels of the chickens 
decreased, leading to the inhibition of the blood-stage malaria parasites. This indicated that the 
parasites not only needed pantothenate to survive, but also that they could not produce it themselves 
[2].  It has since been shown that pantothenate is the only water-soluble vitamin that erythrocyte 
stage P. falciparum parasites are unable to survive without [2]. It has also been shown that 
pantothenate is readily taken up into Plasmodium-infected red blood cells, but that pantothenate is 
not taken up into uninfected red blood cells [12]. The uptake into the parasitized cells happens via 
the ‘new permeation pathway’ (NPP) that the parasite includes within the erythrocyte [12], whereby 
pantothenate is then taken into the cell (in humans) by a low affinity, H+-coupled pantothenate 
transporter [13]. 
Biotin Thiamine 
Pantothenate 
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Even though it seems as if various vitamins play an important role in the proliferation of Plasmodium, 
Divo et al. established P. falciparum’s absolute requirement for extracellular pantothenate by 
[3H]hypoxanthine incorporation, in which an 80% decrease was seen in parasite proliferation when 
pantothenate was not present in growth media [7]. These results were confirmed by Saliba et al., 
who also showed that P. falciparum does not have an absolute requirement for any other water-
soluble vitamin [13], thereby highlighting the absolute necessity of pantothenate within the parasite. 
 
1.4 Coenzyme A and Malaria 
1.4.1 Coenzyme A biosynthesis in Plasmodium 
Pantothenate is metabolized in living organisms to produce coenzyme A (CoA), an essential cofactor 
in both prokaryotes and eukaryotes that is synthesized in bacteria, plants and mammals [14-16]. The 
biosynthesis of CoA from pantothenate takes place through a universal five-step enzymatic pathway 
(Figure 1.3). The five enzymes that catalyze this pathway are pantothenate kinase (PanK), 
phosphopantothenoylcysteine synthetase (PPCS), phosphopantothenoylcysteine decarboxylase 
(PPCDC), phosphopantetheine adenylyltransfrease (PPAT) and dephospho-coenzyme A kinase 
(DPCK).  
Figure 1.3: The universal, five-step enzyme mediated CoA biosynthesis pathway, from 
pantothenate to CoA. See text for details.  
In the first step, pantothenate is phosphorylated by PanK, yielding 4’-phosphopantothenate, which 
subsequently undergoes a condensation reaction (amide formation) with a cysteine molecule, 
mediated by PPCS, to form 4’-phosphopantothenoylcysteine. In most eukaryotes, PPCS has a 
preference for ATP for this conversion, where in bacteria, such as Staphylococcus aureus, it has a 
preference for CTP instead, however it is unknown which PfPPCS prefers. PPCDC decarboxylates 
the cysteine moiety of 4’-phosphopantothenoylcysteine to form 4’-phosphopantetheine, which, in the 
fourth step, undergoes the addition of an adenylyl group by PPAT forming dephospho-CoA. In the 
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final step, DPCK catalyzes the phosphorylation of dephospho-coenzyme A at the 3’ position on the 
ribose to form the final product, CoA [4]. 
 
Putative genes encoding all five enzymes required for CoA formation from pantothenate have been 
identified in the P. falciparum genome [2]. The first four enzymes are predicted to localize to the P. 
falciparum cytosol. The last enzyme in the pathway, DPCK, is predicted to localize to the apicoplast, 
the non-photosynthetic, plastid relic present in most apicomplexan parasites [2]. None of the 
enzymes encoded by these genes have thus far been characterized in any detail, since they are 
notoriously difficult to overexpress and purify from bacterial systems. Various attempts by different 
research groups have been made to produce pure PfPanK using cell-free protein expression 
systems, heterologous expression from codon-harmonized and -optimized genes and by removal of 
expression-hampering sequences [17]. Unfortunately, none of these have been effective to date. 
Nevertheless, some information has been gathered for the activity of PanK in P. falciparum lysates 
(to be discussed in detail in Chapter 3). 
 
Currently, all the information known regarding pantothenate utilization—and consequently CoA 
biosynthesis in Plasmodium—is based on knowledge obtained from the blood-stage of the parasites. 
No information regarding the liver and mosquito stages is currently available. 
 
1.4.2 Functions of CoA in Plasmodium 
Little is known about the specific functions of CoA in the erythrocytic stage of the parasites’ life cycle. 
In general, it is known that CoA acts as an acyl group carrier in all living organisms, since it contains 
a thiol group that can undergo esterification with carboxylic acids, thereby activating them for 
nucleophilic attack or for enolate formation. This is important in many cellular metabolic processes 
such as the all-important first step of the Krebs cycle, fatty acid biosynthesis and regulation, 
biosynthesis of sterols and amino acids, and the post-translational modifications of proteins, among 
others [17, 18]. It is estimated that up to 9% of enzymes in all living organisms make use of CoA or 
one of its thioesters [2].  
Although CoA is important in the Krebs cycle, it is known that blood-stage Plasmodia do not make 
use of the Krebs cycle as its primary source of energy. Instead, these parasites rely on glycolysis for 
energy production [19]. It was shown by Sharma et al. that glucose consumption in parasite-infected 
red blood cells are up to 100-fold higher than for the uninfected red blood cells, supporting the 
parasites’ dependence on glycolysis [19]. 
P. falciparum possesses its own fatty acid biosynthesis pathway, where it uses CoA and pyruvate 
as substrates. It was therefore proposed that in the erythrocytic stage, where fatty acids are important 
for protein post-translational modifications and membrane biosynthesis, the parasite’s absolute 
requirement for CoA in this stage is due to these functions [17]. It was however recently discovered 
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that fatty acid biosynthesis can also be blocked in malaria, by targeted deletion of a crucial enzyme 
involved in fatty acid biosynthesis (FabB/F), without any effect on the blood-stage replication. This 
renders fatty acid biosynthesis non-essential for the survival of the parasite, thus making it a poor 
drug target in malaria [20].  
In addition to the biosynthesis of fatty acids, CoA is also involved in fatty acid modification. This 
occurs when the cofactor is attached to fatty acids by acyl-CoA synthetase causing the activation of 
the fatty acids. The P. falciparum genes encoding for the acyl-CoA synthetases are expressed during 
the erythrocytic stage of the parasites’ lifecycle. Although red blood cells also contain active acyl-
CoA synthetase, the activity of this enzyme is up to 20-times higher in a parasite-infected 
erythrocytes, indicating its possible importance in fatty acid activation, rather than in its ability to 
biosynthesize fatty acids [17]. 
Recently, however, an analysis of P. yoelii’s (a rodent malaria parasite) proteome and transcriptome 
in liver stage found that type II fatty acid synthesis enzymes were present in the liver stage proteome. 
Type II fatty acid synthesis gene transcription has also been shown to be upregulated in liver stage 
compared to levels in the erythrocytic stage. In addition, it was found that an inhibitor of FabG, an 
important enzyme in fatty acid chain elongation, was able to inhibit in vitro parasite proliferation, thus 
suggesting that fatty acid biosynthesis might still be a possible target in liver stage of Plasmodium 
parasites [20]. 
Taken together, the universal occurrence of the CoA biosynthesis pathway and the importance of 
CoA in all living organisms, in addition to the needs of the Plasmodium for this cofactor in different 
life stages, make this biosynthetic pathway an attractive target for antimalarial drug development. 
 
1.5 Targeting CoA Biosynthesis in Plasmodium  
The aim to develop new antimalarials has led to a search for new possible drug targets. Different 
approaches have been used to illustrate that CoA biosynthesis is a novel drug target in P. falciparum. 
One such approach is based on the concept of chemical rescue where assays have been developed 
to screen for inhibitors (varying in their chemical structure) of vital metabolic pathways and then 
rescuing the antimalarial effect by the addition of CoA or metabolites of the pathway [21]. An 
alternative approach to validate the CoA biosynthesis pathway as a potential antiplasmodial drug 
target, has been to synthesize pantothenate analogues using the core structure of pantothenate, the 
native substrate of the CoA biosynthesis pathway and then testing these compounds for a 
antimalarial effect. The synthesis of pantothenate analogues should allow these compounds to 
interfere with Plasmodium’s ability to utilize the vitamin. The inhibition of parasite growth by 
pantothenate analogues is based on the essentiality of pantothenate for blood-stage parasite 
survival in vitro. The various compounds that have been tested in the past by various studies, some 
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of which have been developed to be vanin resistant in order to retain their potency in blood serum, 
are discussed in the following section. 
1.5.1 Pantothenate Analogues 
1.5.1.1 Pantothenol 
Pantothenol (Figure 1.4), or provitamin B5, is a pantothenate analogue in which the carboxylic acid 
group is reduced to a primary hydroxyl group. It is a compound commonly used in consumer products 
from multivitamins to cosmetic products. It has been shown that no significant adverse effects are 
noted, even after long term use, even when used or ingested in high concentrations by humans [21]. 
However, in vitro studies have shown that it prevents proliferation in a variety of different bacteria 
[22]. Consequently, pantothenol was tested by Saliba et al. on blood-stage P. falciparum parasites 
and shown to have antimalarial activity in vitro [23].  
 
Figure 1.4: The structure of pantothenol. This pantothenate analogue merely has a 
hydroxyl group in the position where pantothenate has a carboxyl group (indicated in 
orange).  
Since pantothenol can act as a provitamin in some organisms by being oxidized to pantothenate, 
Saliba et al. tested to see whether this was the case in Plasmodium as well; however, blood-stage 
parasites could not survive in pantothenate-free media that was supplemented with pantothenol. 
They found that instead of supporting the proliferation of the parasite, pantothenol actually inhibited 
parasite proliferation by competing with pantothenate in the conversion to its phosphorylated form, 
thus implicating the possible inhibition of PanK [13]. 
1.5.1.2 CJ-15,801 
The pantothenate analogue, CJ-15,801 (Firgure 1.5) is a compound isolated from the fungus 
Seimatosporium sp.,CL28611. The only difference in structure between CJ-15,801 and pantothenate 
is the inclusion of a double bond in the β-alanine moiety of the vitamin. 
 
Figure 1.5: The structure of CJ-15,801. This pantothenate analogue has a double bond 
between carbons 2 and 3 as indicated in orange, where pantothenate has a single bond.  
CJ-15,801 was previously shown to have antibacterial effects, even on multi-drug resistant S. aureus 
[24]. It was therefore investigated by Saliba et al. for its antiplasmodial properties against P. 
falciparum [23]. Blood-stage parasites were incubated with CJ-15,801 in the presence of 
physiological concentrations of pantothenate (1 µM), and it was found that CJ-15,801 inhibits 
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parasite proliferation at concentrations above 250 µM, without an effect on the host cell line [23]. 
However, the antiplasmodial effect of CJ-15,801 was reversed when pantothenate concentrations 
were increased, but it was only completely reversed at very high pantothenate concentrations 
(around 100-200 µM) [23]. This confirmed that this compound is targeting the biosynthesis pathway 
that utilizes pantothenate in order to form CoA. 
1.5.1.3 Pantoyltauramides 
One of the first pantothenate analogues to be tested against malaria was pantoyltauramide (Figure 
1.6 A), an analogue in which the carboxylic acid has been substituted for a sulphonamide group. 
When tested in vivo against different types of avian malaria parasites such as P. relictum, P. 
gallinaceum, and P. lophurae, this compound was found to be almost inactive when incorporated 
into the birds’ diet [25]. However, when administered intravenously at a dose of 400 mg/kg body 
weight, proliferation of P. gallinaceum was inhibited in chickens [26].  
 
        
 
 
Figure 1.6: (A) The structure of pantoyltauramide, one of the first pantothenate analogues 
to be tested for its antiplasmodial activity, (B) the most potent N-substituted 
pantoyltauramide in the study done by Trager in 1971 [27] and (C) the structure of N-
substituted pantoyltauramides (where R- groups are specified in the grey block).  
In an attempt to make the pantoyltauramides more active when orally administered, the 
pantoyltauramide structure was modified further by inclusion of additional groups to the sulfonamide 
functionality, thus producing a library of new compounds called the N-substituted pantoyltauramides 
(Figure 1.6 C) [27]. The most potent of the N-substituted pantoyltauramides in this library (Figure 1.6 
B) was found to be approximately four times more potent than quinine when tested against P. 
gallinaceum in chickens [28]. 
A B 
C 
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1.5.2 N-substituted Pantothenamides 
Another class of pantothenic acid analogues is the N-substituted pantothenamides (PanAms) (Figure 
1.7A).  
 
 
Figure 1.7: The structure of (A) a synthetic general N-substituted pantothenamide and 
(B) naturally occurring pantetheine. Pantetheine is essentially an N-substituted 
pantothenamide with an ethylthiol moiety as the R-group. 
 
Although these compounds are technically pantothenate analogues (they have an amide 
functionality instead of a carboxylic acid), they are structurally more closely related to the natural 
occurring pantothenamide, pantetheine (containing a cysteamine moiety, Figure 1.7 B). Pantetheine 
is present in certain bacteria and is believed to be a degradation product of CoA, however, it also 
has the ability to be phosphorylated by PanK to feed back into the biosynthesis of CoA in a salvage 
pathway to reproduce CoA (Figure 1.8) [29]. Currently it is still unknown if pantetheine is present in 
Plasmodium parasites. 
  
Figure 1.8: The CoA salvage pathway, starting with natural compound, pantetheine, 
which also undergoes phosphorylation by PanK after which PPAT and DPCK convert it 
to CoA.  
In the past a large number of N-substituted pantothenamides were tested on blood-stage parasites 
by Jackowski et. al [30], Park et. al [31], Strauss et. al [32], Saliba et. al [33-35] and others [36]. 
Fortunately, many of these analogues had an effect on Plasmodium’s proliferation and, because of 
               
 A B 
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their similar structure to pantothenate, some of them have been shown to interfere with the 
phosphorylation of pantothenate by PanK [33]. This in turn supports the theory that pantothenate 
analogues target the CoA biosynthesis pathway. In fact, a study by Spry et al. [33] found that 
PanAms (Figure 1.7 A) are the most potent pantothenate analogues against P. falciparum, with N-
phenethyl-PanAm (N-PE-PanAm) being the most potent in vitro, with an IC50 of 20 ± 3 nM. This IC50 
is comparable to chloroquine, an antimalarial used from 1947 until the late 1950s [37], with an IC50 
of 15 nM [33, 34, 38].  
 
1.5.3 Pantetheinase (Vanin) 
Unfortunately, the use of PanAms for clinical treatment of malaria is not possible since these 
compounds are prone to degradation by vanins (hydrolase enzymes that target non-peptide carbon-
nitrogen bonds), specifically pantetheinases, in the blood serum [39]. When looking at in vivo 
conditions, pantetheine gets degraded to form pantothenate and cysteamine by the hydrolysis of the 
scissile amide bond (Figure 1.9). Since the PanAms have the same core structure as pantetheine, 
containing an amide bond in the same position, these compounds are also susceptible to 
degradation, thus rendering them ineffective as antiplasmodials in the presence of blood serum [33].  
 
Figure 1.9: Both naturally occurring pantetheine and synthetically synthesized 
pantothenamides are degraded by vanins to form pantothenate and the corresponding 
amine. 
Various strategies have been employed to overcome this shortcoming. One specific strategy is 
combination therapies of PanAms with pantetheinase inhibitor compounds (Figure 1.10). These 
compounds, which are also PanAm analogues, but which have the scissile amide bond replaced by 
a ketone, act as selective, competitive vanin inhibitors that inhibit vanin activity in rat plasma as low 
as nanomolar concentrations [40]. The potential of these compounds to also inhibit P. falciparum 
parasite proliferation was also investigated and it was found that they do have antiplasmodial activity, 
however with less potency (low micromolar range) than existing PanAms [41]. 
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Figure 1.10: Structure of a pantothenate analogue, RR6, which acts as the most potent 
vanin inhibitor.  
 
1.5.4 PanAm Analogues Resistant to Pantetheinase-mediated Degradation 
A second strategy in circumventing the pantetheinase degradation effects on PanAms, is the design 
of compounds that are resistant to degradation by this blood serum enzyme. This has the added 
advantage that only one specific therapy needs to be used, i.e. without the added complication of 
having two compounds that could potentially be toxic towards humans. Various degradation-resistant 
modifications to the PanAm structure have been attempted by investigators, with the following 
modifications showing the most promise.  
1.5.4.1 Sterically hindered N-substituted PanAms 
It was found that modification of PanAms by substituting the β-alanine moiety for a glycine to produce 
α-PanAms (Figure 1.11 B), or substituting the β-alanine moiety for γ-aminobutyric acid to produce 
HoPanAms (Figure 1.11 C), makes these compounds less susceptible to pantetheinase-mediated 
degradation by shifting the position of the amide bond. This resistance to degradation however 
comes at the cost of a loss in potency [34]. This becomes evident when studying the antiplasmodial 
activity of N-PE-PanAm: when testing the antiplasmodial activity in vitro with no pantetheinase 
present, this compound has an IC50 of 20 ± 3 nM, however, when pantetheinase is present in the 
media, a shift in IC50 to 53 ± 11 μM is observed [33]. The α- and HoPanAms have been shown to 
have increased IC50s of 3.4 ± 0.8 μM and 2.1 ± 0.1 μM, respectively, in the absence of 
pantetheinases [34], which suggests the core pantothenate structure is necessary in order for the 
PanAm to be potent. This realization led to further modification of the N-PE-PanAm structure in order 
to produce PanAms that are stable in serum while retaining their antiplasmodial activity.  
 
Figure 1.11: The structures of synthesized pantothenamides (A) N-PE-PanAm, and its (B) 
α-PanAm and (C) HoPanAm counterparts. The β-alanine moiety is highlighted in orange, 
the glycine moiety highlighted in blue and the γ-aminobutyric acid highlighted in green. 
C 
A  B 
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To overcome the loss of potency, N-PE-PanAm was modified to include a methyl substituent 
adjacent next to the amide that is normally cleaved by the vanins, forming N-phenethyl-α-methyl-
PanAm (N-PE-α-Me-PanAm) (Figure 1.12). This methylated compound was then tested in the 
presence of pantetheinases and shown to be more resistant to degradation while still retaining its 
potency (0.06 ± 0.02 μM) [42]. Importantly, methylated-PE-PanAm was significantly more resistant 
to degradation by pantetheinase compared to N-PE-PanAm, and, crucially, still acted on-target, as 
demonstrated by the fact that addition of excess extracellular pantothenate antagonized its 
antiplasmodial activity [2]. Furthermore, it has limited cytotoxicity to mammalian cells [36]. However 
it must be noted that the compound tested was the mixture of the two epimers, (R)- and (S)-N-PE-
α-Me-PanAm. The specific activities of the two compounds have not been investigated to date. 
 
Figure 1.12: The structure of the synthetic PanAm, N-PE-α-Me-PanAm, that was shown to 
be more resistant to degradation by pantetheinases. The yellow highlighted group 
indicates the methyl group added to the compound to prevent cleavage of the amide bond 
adjacent to it.  
 
1.5.4.2 N-Substituted triazole bio-isosteres 
Recently, another strategy to increase the resistance of PanAms towards pantetheinase-mediated 
degradation has been illustrated by exchanging the scissile amide bond with a triazole bio-isostere 
[35]. In total 19 triazoles were synthesized and tested for antiplasmodial activity against P. falciparum 
with all compounds tested having sub-micromolar IC50 values, with 2 of them having IC50 values of 
~50 nM against blood-stage parasites (Figure 1.13), only slightly higher than that of chloroquine [35]. 
These compounds have been shown to be on target after the addition of extracellular pantothenate 
shifted their antiplasmodial activity and it has been speculated that they have an effect on PanK 
phosphorylation [35]. 
 
Figure 1.13: The structure of the N-substituted triazole bio-isosteres with IC50  values of 
~50 nM against blood-stage P. falciparum parasites. N5-triazole has an IC50 of 56 ± 5 nM 
and N6-triazole has an IC50 of 55 ± 5 nM. 
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1.5.4.3 N-Substituted PanAm bio-isosteres with an inverted amide group 
A recent patent application on PanAms as antimicrobials has employed an additional strategy to 
produce stabile PanAms in the presence of pantetheinase. In this simple, yet elegant modification, 
the scissile amide bond has been replaced by an amide bond in the inverse orientation when 
compared to that of normal PanAms. The resulting PanAm bio-isosteres are resistant to degradation 
by pantetheinases, and when compared to the parent compound, have no loss of potency. A small 
library of compounds has been tested, including the inverted amide variant of N-PE-PanAm (Figure 
1.14 B) which had an IC50 of 0.12 µM against P. falciparum. The ortho-fluoro derivatives of N-PE-α-
Me-PanAm were also tested as the individual R- and S-stereoisomers (Figure 1.14 C and D), with 
IC50 values of 0.004 µM and 0.21 µM against P. falciparum being reported. This makes the R-
stereoisomer derivative of N-PE-α-Me-PanAm the most potent of these compounds, when tested 
against P. falciparum, with compound CXP18.6-052 (Figure 1.14A), the second most potent with an 
IC50 of 0.008 µM [32]. 
  
Figure 1.14: (A) The structure of compound CXP18.6-052, the most potent of the reversed 
amides tested against P. falciparum , (B) the structure of the inverted amide for of PE-
PanAm, and (C &D) R-  and S-stereoisomers of the ortho-fluoro derivative of N-PE-α-Me-
PanAm. 
1.6 Mode of Action of the PanAms 
The mode of action of pantothenate analogues in P. falciparum is still currently unknown. It is also 
possible that different pantothenate analogues have different modes of action involving different 
targets in the biosynthesis and/or utilization of CoA. For this particular study our main focus is on the 
mode of action of PanAms, and therefore possible targets of these compounds will be discussed in 
this regard.  
 
Previous studies have shown that the addition of pantothenate to the parasites extracellular 
environment reverses the PanAms’ antiplasmodial activity [34, 36]. This suggests that the PanAms 
target the enzymes involved in CoA biosynthesis and/or the downstream processes that use CoA or 
A B 
C D 
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its thioesters [43]. Since no other information regarding the mode of action of PanAms is known for 
P. falciparum parasites, we considered what is known for these compounds when studied in bacteria. 
 
The antibacterial mode of action of the PanAms has mainly been studied in Escherichia coli and S. 
aureus. Also, although various PanAms inhibited bacterial growth, most of these studies focused on 
N-pentyl pantothenamide (N5-Pan) and N-heptyl pantothenamide (N7-Pan). Three possible modes 
of action have been proposed for the PanAms in bacteria, illustrated in Figure 1.15 for N5-Pan: (1) 
PanAms inhibit the PanK, the first enzyme in the CoA biosynthesis pathway, inhibiting the 
phosphorylation of pantothenate and therefore shutting down the CoA biosynthesis pathway; (2) 
when PanAms act as competing substrates, they can be phosphorylated by PanK and metabolized 
by PPAT and DPCK downstream in the pathway. This allows for the formation of CoA 
antimetabolites. These antimetabolites will either compete with the production of CoA and lower CoA 
intracellular concentrations to levels that are insufficient to sustain bacterial growth, or cause the 
inhibition of CoA-dependent processes and enzymes; (3) a specific CoA-dependent process, fatty 
acid biosynthesis is inhibited. This occurs by the formation of crypto-acyl carrier proteins (crypto-
ACPs) where the 4’-phosphopantothenamide moiety is transferred to an acyl carrier protein (ACP) 
instead of the 4’-phosphopantetheine moiety it usually needs from CoA. These crypto-ACPs are 
inactive due to the lack of a terminal thiol (which they usually obtain from CoA) necessary for fatty 
acid biosynthesis [33, 44, 45]. This last option was supported by a previous study that indicated that 
the PanAms do not inhibit bacterial PanK, since the PanAms are still phosphorylated once taken up 
into the bacterial cell, specifically in E. coli. In this organism it was therefore found that the main 
growth inhibition takes place via inhibition of fatty acid biosynthesis [30, 33]. However, recent findings 
have also indicated that PanK in S. aureus is partially inhibited by PanAms via trapping of the 
phosphorylated product [31, 34] and once the phosphorylated product is released (which takes place 
very slowly) they can be metabolized further to inhibit fatty acid biosynthesis [30]. The specific mode 
of action for this inhibition of fatty acid biosynthesis is not clearly defined yet. 
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Fig 1.15: The three main biological targets for PanAms in bacteria, illustrated with N5-
Pan: (1) PanK, the first enzyme in the CoA biosynthesis pathway; (2) the CoA-dependent 
enzymes and processes, once the antimetabolite is formed; and (3) fatty acid 
biosynthesis, when the antimetabolite formed acts as a substrate for the enzyme AcpS 
to form the inactive crypto-ACP instead of the catalytically active holo-ACP [46] 
(Reproduced with permission from [33], Copyright John Wiley & Sons, Inc.). 
When extrapolating this knowledge to P. falciparum, there are four proposed modes of action for 
PanAm inhibition (Figure 1.16). In Target 1 PanAms could interfere with the transport of pantothenate 
by inhibiting the essential primary pantothenate transporter in P. falciparum, leading to the 
deprivation of the essential vitamin. This is not considered a target in bacteria, since bacteria have 
the means to synthesize pantothenate de novo which is not the case for P. falciparum parasites. It 
has been recently discovered by Kehrer et al. that in P. berghei the pantothenate transporter, PAT, 
is essential for the secretion of vesicles needed for the transmission of the parasite between the 
human host and the mosquito [48]. This supports pantothenate transport as possible target. Target 
2 involves the inhibition of PanK, the first CoA biosynthetic enzyme, which would shut down CoA 
production. Alternatively, PanAms can be phosphorylated by PanK as substrates. This allows for 
these compounds to become metabolically activated as substrates for PPAT and DPCK, converting 
them into CoA antimetabolites. Such a transformation could result in growth inhibition in two ways: 
(Target 3) the decrease of CoA levels to concentrations below what is required to sustain parasite 
survival or (Target 4) the direct inhibition of one or more CoA-requiring processes by the CoA 
antimetabolites. It has been shown that fatty acid biosynthesis is not essential in blood-stage P. 
falciparum parasites [47, 48] and blood-stage parasites rely exclusively on glycolysis for their energy 
needs. Consequently, these parasites do not use the Krebs cycle (with its many acyl-CoA 
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intermediates) in this life-stage [19]. It is therefore unlikely that fatty acid biosynthesis and the Krebs 
cycle are targets for CoA antimetabolites. However, since there are various processes relying on 
CoA, other targets might come into play. In addition, fatty acid biosynthesis has been implied to be 
important in the liver stage of P. falciparum [20] and therefore these compounds might act on different 
targets in the different life stages of the parasite. 
 
Currently it is unknown which of the four targets is the main point of inhibition for PanAms. Various 
studies have shown the inhibition of pantothenate uptake and phosphorylation by pantothenate 
analogues [13, 23]. A recent study has shown that PanAms inhibit pantothenate uptake and 
phosphorylation by these compounds competing with pantothenate uptake and phosphorylation [49]. 
It has also been shown that pantothenamides are phosphorylated by PfPanK present in parasite 
lysate; therefore, it seems as if these compounds act as substrates for PanK [42, 49]. These findings 
eliminates target 1 and 2 as possible targets for PanAm inhibition and elude to target 3 and 4 as 
possibilities. Therefore further research is needed to investigate whether the antimetabolites are 
actually formed, and if so, what the effects of these compounds are on the biochemistry of the malaria 
parasite. 
 
Figure 1.16: The proposed mechanisms of action for the PanAms in P. falciparum: (1) 
Interference with the pantothenate transporters; (2) inhibition of PanK; (3) CoA 
antimetabolites could cause a decrease in CoA levels to concentrations lower than the 
parasite needs to survive or (4) the CoA antimetabolites inhibit one or more downstream 
CoA-requiring processes directly.  
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1.7 Aims of this Study 
The purpose of this project is to shed light on the mode of action of PanAms’ inhibition of P. 
falciparum parasite proliferation. Three main aims were set out for this study in order to lay ground-
work for future research in finding the exact point of action of PanAm inhibition. Not only will this 
allow CoA biosynthesis to be considered as a new drug target in P. falciparum, but importantly, it will 
also increase knowledge on unknown parasite biochemistry.  
Aim 1: Establish the minimum extracellular pantothenate concentration needed for parasite 
survival  
Ultimately we want to determine what the critical amount of CoA is for parasite survival. In doing so 
we can determine the threshold needed for PanAms to interfere with CoA biosynthesis. However, 
this is not an easy determination to make since parasites obtain CoA from pantothenate received 
from the host red blood cell that in turn obtains pantothenate from extracellular sources. We therefore 
set out to determine the minimum required pantothenate needed for the survival of blood-stage P. 
falciparum parasites.  
Objective 1: Determine parasite survival without pantothenate present  
In order to achieve this, custom RPMI media without pantothenate present must be obtained since 
all commercially available RPMI-1640 media contains ~1 µM pantothenate. P. falciparum 3D7 is 
then cultured in this media under otherwise normal culturing conditions to determine how long they 
can survive without any extracellular pantothenate available to them.  
Objective 2: Determine the minimum amount of extracellular pantothenate necessary for P. 
falciparum survival 
Once we know how long blood-stage parasites can survive without pantothenate, we can determine 
the minimum amount of pantothenate needed for parasite survival by again culturing P. falciparum 
3D7 strain in pantothenate-free media, supplemented with varying concentrations of pantothenate. 
Ultimately these two experiments will lay a foundation for future studies to determine the minimum 
amount of CoA required for parasite survival.  
 
Aim 2: Determine if N-PE-α-Me-PanAm is metabolized by CoA biosynthetic enzymes as 
substrate to form CoA antimetabolites  
Evidence that the PanAms can be converted to the corresponding CoA antimetabolites by the CoA 
biosynthetic enzymes present in P. falciparum parasites will support the mode of action of PanAms 
that is based on either the lowering CoA levels, or the inhibition of processes in the parasite that 
depend on CoA.  
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Objective 1: Validate an analytical technique for CoA antimetabolite detection 
Several analytical chromatography techniques are available in our laboratory for the detection of 
CoA and intermediates of the pathway. Our first objective was therefore to determine which 
technique would suite our application (using parasite lysate) the best. 
Objective 2: Analysis of PanAm conversion in P. falciparum lysate 
In this case we analysed the conversion of N-PE-α-Me-PanAm to the corresponding CoA 
antimetabolites in the presence of lysate from isolated P. falciparum parasites. 
Objective 3: Analysis of N-PE-α-Me-PanAm conversion in P. falciparum cultures in vitro. 
We also investigated the conversion of PanAms in P. falciparum cultures treated with a non-lethal 
dose of PanAm to determine if any conversion of the compound is taking place under culture 
conditions. 
 
Aim 3: Synthesis and evaluation of the effect of a PanK inhibitor that is not a pantothenate 
analogue.  
To support that PanAms do not inhibit PanK, but are rather metabolized downstream in the pathway 
we set out to prepare a PanK inhibitor that is not a pantothenate analogue. Recently studies have 
shown that human PanK can be inhibited by tricyclic methylthiophenyl propanamides (TMPs) that in 
structure are not related to pantothenate at all [50]. TMPs bind to the ATP-PanK complex to induce 
their inhibitory effect and were shown to impair CoA levels at increasing concentrations of TMPs 
[50]. We therefore want to prepare a TMP analogue and test it on P. falciparum to see if it has any 
inhibitory effect on PfPanK and parasite prolliferation. If so, it should inhibit by lowering CoA levels 
since it shuts down CoA biosynthesis at the first enzyme. This can then be used for future studies 
as a tool to compare to PanAm as inhibitors in order to determine if PanAms lower CoA levels in a 
different way—the difference being that the TMP analogue cannot act as alternative substrates and 
the pantothenamides can, since they are pantothenate analogues.  
Objective 1: Synthesis and purification of TMP  
In order to test TMPs as a P. falciparum inhibitor, one of these compounds had to be synthesized. 
This was attempted by using published protocols in literature [50].  
Objective 2: Test TMP as P. falciparum PanK inhibitor 
TMP was established in literature as human PanK inhibitors by using a discontinuous radioactive 
assay. These results should be confirmed by testing TMPs on human PanK 3, which is available in 
our laboratory. Once this has been established we can test the effect of this compound on P. 
falciparum in parasite lysate using the same discontinuous radioactive assay. 
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Objective 3: Test TMP as inhibitor of P. falciparum proliferation 
TMP will be tested as inhibitor of P. falciparum parasite growth in culture and if it is an inhibitor the 
IC50 will be determined. 
 
The aims and objectives set out in this study will form the pilot study in the quest to determine the 
specific mode of action of PanAms in order to develop these compounds further as inhibitors of P. 
falciparum in various stages of the parsites life cycle in future studies to come.  
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Chapter 2: Materials and Methods 
2.1 Materials 
2.1.1 General reagents  
All general reagents and chemicals, solvents, silica and thin-layer chromatography (TLC) plates used 
for synthesis were purchased from Sigma-Aldrich. SYBR Safe fluorescent DNA stain (10 000 × 
concentrate in DMSO) for P. falciparum growth assays were acquired from Invitrogen. Novagen’s 
KOD Hot start DNA Polymerase Kit was bought from Merck. Mycoplasma removal agent (MRA) was 
from Biorad. Mycoplasma DNA was a kind gift from Dr. Annelise Botes (Department of Biochemistry, 
Stellenbosch University). Nancy-520 gel dye was obtained from Sigma-Aldrich. 
2.1.2 Plastics and glassware 
For culturing, Kymex and Falcon 15 ml and 50 ml centrifuge tubes as well as Greiner Cellstar ® 75 
cm2 (250 ml) tissue culture flasks and NEST 25 cm2 (60 ml) tissue culture flasks were used for all in 
vitro P. falciparum culturing. For all the assays, cultures were incubated in sterile, clear, NEST 96-
well flat bottom cell culture plates and fluorescent assays analyzed in Grenier Bio One black 96-well 
flat bottom plates. For the malstat assays, clear Grenier Bio One 96-well flat bottom plates were 
used. 1 ml, 5 ml, 10 ml and 60 ml Surgi Plus syringes were purchased from Stellenbosch Medical 
Suppliers and 1.5 ml and 2.0 ml centrifuge tubes where obtained from Scientific Specialties, Inc.  
2.1.3 Culture medium and media components 
Standard RPMI-1640 culture media as well as HEPES, sodium bicarbonate, glucose and 
hypoxanthine used to supplement the media were purchased in powder form from Sigma-Aldrich 
and were all suitable for cell culture. The gentamycin was purchased from Sigma-Aldrich in liquid 
form, and Albumax II serum acquired from Professor Peter Smith, Division of Pharmacology at the 
University of Cape Town, who acquires it from Thermo Fisher Scientific Inc. The custom made, 
pantothenate free media was first made up using components bought from Sigma-Aldrich. Later it 
was custom made by an American based company, AthenaES and was acquired in liquid form 
(containing Glutamax instead of L-glutamine). Other components used in assays were purchased in 
powder form from Sigma-Aldrich and the low oxygen gas mixture used to gas cultures was obtained 
from Afrox. 
 
2.1.4 Human erythrocytes 
Human A+ blood was used for all malarial cell cultures and was obtained biweekly from the Western 
Cape Blood Bank at Vergelegen Medi-Clinic, Somerset West, South Africa. The work performed in 
this study was performed in the laboratory of the co-supervisor, Prof Erick Strauss. Prof. Strauss has 
ethical clearance from the The Health Research Ethics Committee of Stellenbosch for use of human 
blood in cell culture medium. 
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2.1.5 Plasmodium falciparum parasites 
The P. falciparum strain 3D7 parasites used in this study were available in the laboratory of Prof. 
Erick Strauss (co-promotor to this study) in the Department of Biochemistry at Stellenbosch 
University. 
2.1.6 N-substituted Pantothenamides and CoA biosynthesis metabolites 
N-PE-α-Me-PanAm used in this study was synthesized by Dr. Leanne Barnard (Department of 
Biochemistry, Stellenbosch University) as part of another study [1]. Its purity was confirmed by 1H, 
13C NMR and High Resolution Mass Spectrometry (HRMS) analysis prior to being stocked. These 
compounds are usually stored at -20 °C at a concentration of 200 mM in either DMSO or 50% 
acetonitrile/water.   
Pantothenate, pantetheine, dephospho-CoA, and CoA, were obtained from Sigma-Aldrich. 4’-
phosphopantetheine was synthesized from pantetheine using a S. aureus PanK enzyme. 
2.1.7 Bacterial Enzymes 
S. aureus PanK and E. coli PPAT and DPCK were already available in the laboratory of Prof. Erick 
Strauss and were expressed and purified from E. coli according to published procedures [2, 3]. 
2.1.8 Spectrophotometry and fluorimetry 
All spectrophotometric and fluorometric readings were done in 96-well plates with a Varioskan 
multimode reader (Thermo Fisher Scientific Inc.)  
2.1.9 High Performance Liquid Chromatography (HPLC) 
HPLC was performed using the Opti-guard® 1 mm C18 guard column from Sigma-Aldrich, in 
combination with the Phenomenex Luna 5u C18(2) 100A 250 x 4.60 mm column from Separation 
Sciences. These were used on an Agilent/Hewlett Packard Series 1100 HPLC system from Cohesive 
Technologies and Agilent Technologies with in line FLD-fluorescence and UV detectors. HPLC-
grade CHROMASOLV solvents (acetonitrile and methanol) used for HPLC were acquired from 
Sigma-Aldrich.  
2.1.10 Liquid chromatography Mass Spectrometry (LCMS) 
All LCMS and Electron Spray Ionisation Mass Spectrometry (ESI-MS) analyses were done at the 
Central Analytical Facility (CAF) at Stellenbosch University using a Waters 2690 Separations Module 
with a Waters 996 Photodiode Array Detector for the liquid chromatography separations, linked to a 
Waters Micromass Quattro mass spectrometer for mass analysis. The data were then analyzed 
using MassLynx software. 
2.1.11 Nuclear Magnetic Resonance (NMR) Spectroscopy 
All NMR analyses were done at CAF (Stellenbosch University) on a Varian VXR 300 MHz “R2-D2” 
NMR spectrometer and a Varian Inova 400 MHz NMR spectrometer. The data were then analyzed 
using MestReNova software. The analyses were run in deuterated solvents (chloroform-d, dimethyl 
sulfoxide-d6 and deuterium oxide) obtained from Sigma-Aldrich.  
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2.2 Methods 
2.2.1 Preparation of erythrocytes for P. falciparum cultures and experiments 
A fresh bag of A+ red blood cell concentrate (3-5 days old) was collected biweekly and stored at 4 
°C. Before use of the blood in experiments or cultures, it was washed to ensure that any leukocytes 
or proteins still present were removed. This was performed by mixing equal parts blood and RPMI-
1640 media, supplemented with 25 mM HEPES, 23.8 mM sodium bicarbonate, 11.1 mM glucose, 
200 µM hypoxanthine (dissolved in 0.5 M NaOH), 24 µg/ml gentamycin and 0.6% m/v Albumax II 
serum, at pH 7.4 (hereafter called RPMI complete media), in a sterile 50 ml Falcon tube and 
centrifuging it at 1200 x g for 3 min. Supernatant was then discarded and the washing step repeated 
one more time. Thereafter 5 ml media was added to the erythrocytes and they were stored at 4 °C 
and used for no longer than 14 days. 
2.2.2 Continuous P. falciparum cultures 
P. falciparum 3D7 strain was used for all in vitro experiments containing malaria parasites. These 
parasites were maintained in a continuous culture, using similar methods to those described by 
Trager in 1976 [4]. Briefly, the P. falciparum parasites were cultured in A+ human erythrocytes (4% 
hematocrit) in RPMI complete media. The cultures were incubated in ventilated culture flasks (small 
cultures had a volume of 5 ml culture in a 60 ml culture flask and standard cultures had a volume of 
50 ml culture in a 250 ml culture flask), in a low oxygen gas mixture environment (1% oxygen, 3% 
carbon dioxide, 96% nitrogen). Cultures were laid horizontally for maximum surface area exposure 
to the gas mixture, and incubated at 37 °C on a rotary shaker (50 rpm) to encourage synchronous 
cell culture growth. The media on the cultures was changed daily and cultures split on days when 
cultures were in trophozoite stage and parasitemia was high, to prevent cell death and stress caused 
by overpopulation. The cultures were maintained with parasitemia between 5-20%. To split, cultures 
were centrifuged at 750 x g for 3 min, the media removed, and of the pellet, 0.25 – 1 ml was 
transferred to a new falcon tube (dependent on parasitemia), followed by the addition of 1 – 1.75 ml 
washed blood, to maintain the 4% hematocrit in the culture. The rest of the volume was then made 
up to 50 ml by pre-incubated (37ºC) RPMI complete media. 
2.2.3 Synchronization of P. falciparum cultures 
P. falciparum in vitro cultures do not stay in a synchronous phase like they do in vivo, and thus 
cultures need to be synchronized ~4 days before using cultures for experiments. Methods adapted 
from a published protocol by Lambros and Vanderberg [5] were used for this purpose. Briefly, the 
culture media was removed and the erythrocyte and parasite pellet treated with 10 volumes of 5% 
(m/v) filtered, prewarmed D-sorbitol at 37 °C for 10 min, homogenizing the suspension every 2-3 min 
for best synchronization. This process would lyse all parasites in trophozoite stage, thus only leaving 
parasites in ring stage.  
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2.2.4 Determination of parasitemia 
Before cultures were split or experiments were started using P. falciparum, the percentage of 
parasite-infected erythrocytes (parasitemia) was determined. This was done manually by taking 
culture samples and making blood slides. Cells were fixed with methanol and the cells then stained 
with Giemsa working stain (10 ml 10x Giemsa stock in 90 ml 1x PBS buffer). The slides were then 
viewed under a light microscope with a 1000x magnification and the number of parasites (stained 
blue) divided by the number of red blood cells (not stained because they do not have DNA) calculated 
as percentage parasitemia. 
2.2.5 Testing and treatment of cultures for Mycoplasma infection 
Mycoplasma infections are common in cell cultures and thus P. falciparum cultures need to be tested 
regularly for Mycoplasma infections. 
2.2.5.1 Testing for Mycoplasma infection 
A few set of primers are needed to test for the presence of Mycoplasmas in P. falciparum cultures. 
These primers are 5’ primers Myc51 (seq: CGCCTGAGTAGTACGTTCGC), Myc52 (seq: 
CGCCTGAGTAGTACGTACGC), Myc53 (seq: TGCCTGAGTAGTACATTCGC), Myc54 (seq: 
TGCCTGGGTAGTACATTCGC), Myc55 (seq: CGCCTGGGTAGTACATTCGC, Myc56 seq: 
CGCCTGAGTAGTATGCTCGC, and 3’ primers Myc31 (seq: GCGGTGTGTACAAGACCCGA), 
Myc32 (seq: GCGGTGTGTACAAAACCCGA) and Myc33 (seq: GCGGTGTGTACAAACCCCGA). A 
primer mix containing 2 µM of each of the 9 primers was prepared. 
When changing media in cultures (section 2.2.2) an aliquot of the old media was dispensed into a 
centrifuge tube after centrifugation of the blood culture. This supernatant was then heated to 95 °C 
for 15 min and then placed on ice for 5 min to cool. Once cooled, it was centrifuged in a 
microcentrifuge at top speed (16 606 x g) for 3 min and at least 50 µL of this supernatant collected. 
PCR reaction mixtures containing 2.5 µl 10x PCR reaction buffer, 1.75 µl 25 mM MgSO4, 5 µl 2 mM 
dNTPs, 12.25 µl sterile MilliQ water from Novagen’s KOD Hot start DNA Polymerase Kit and 2.5 µl 
2 µM primer mix per sample was made up. 24 µl of this PCR mix was then aliquoted into PCR tubes 
and 1 µl sample supernatant added. In addition to the sample from the blood culture, 2 negative 
controls (one containing no KOD polymerase and one containing no DNA template) were set up, as 
well as one positive control containing 17.1 ρg Mycoplasma DNA. Once heated, 1 µl KOD 
polymerase also from Novagen’s KOD Hot start DNA Polymerase Kit was added to each sample.  
The PCR program ran a 2 min pre-cycle at 95 °C, followed by 40 cycles of 95 °C for 20 seconds, 52 
°C for 10 seconds, 74 °C for 32 seconds and then finally ended on 4 °C. Once the PCR was 
complete, the DNA was run on a 1% agarose gel with TAE buffer, containing 5 µl Nancy-520 gel 
dye. The entire PCR samples with 5 µl loading buffer each were loaded onto the gel, along with 10 
µl of the Universal Ladder (Kapa Biosystems) and the gel run for 65 min at 80 volts in TAE buffer 
and then imaged on a blue light trans-illuminator once completed. 
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2.2.5.2 Treatment of Mycoplasma infection in P. falciparum culture 
If the P. falciparum cultures tested positive for Mycoplasma infection, parasitemia of the culture 
should be determined (section 2.2.4) and a 5 ml culture split into a 60 ml cell culture flask, containing 
4% hematocrit and 2% parasitemia. This culture is then treated with 50 µl Mycoplasma removal 
agent (MRA). The media was changed daily (section 2.2.2) and 50 µl MRA added to the culture 
every time media is changed. The culture was treated for a week before it was tested again for the 
presence of Mycoplasma (section 2.2.5.1), and only if it tests negative is the culture increased to a 
50 ml culture again. Two weeks after the Mycoplasma removal was successful, the cultures were 
tested a second time for the presence of Mycoplasma (section 2.2.5.1) to confirm that all 
Mycoplasmas were removed from the culture during treatment.  
2.2.6 P. falciparum parasite isolation and lysate preparation 
For experiments that made use of P. falciparum cell lysates, cultures were grown to a high 
parasitemia (~10-20%) and parasites isolated on a day when they were in trophozoite stage. For 
isolation, the Plasmodium infected erythrocytes, still suspended in media, were subjected to 0.05% 
(m/v) saponin. Saponin is a plant-derived compound, attacking the cholesterol of cell membranes. 
Since the erythrocyte cells have cholesterol in their cellular membranes where the parasite cell 
membranes lack cholesterol, parasite cells remain intact, while pores form in the erythrocyte cell 
membranes, thus lysing them. The treated cultures are then immediately centrifuged at 2000 x g for 
8 min at 4 °C after which the supernatant was removed and discarded. The remaining cell pellet, 
consisting of predominantly parasite cells, was washed with malaria saline (125 mM sodium chloride, 
25 mM HEPES, 1 mM magnesium chloride, 5 mM potassium chloride, and 20 mM glucose) to 
remove any cell debris still in the pellet. The mixture was centrifuged for 30 seconds at 16 606 x g 
at 4 °C and the supernatant removed. This step was repeated a further 3-4 times until the 
supernatant was clear after the centrifugation step. 
Once isolated, the parasites in the pellet were resuspended in 500 µl malaria saline. Of this, 20 µl 
was transferred to another centrifuge tube and diluted 50x with malaria saline; this was used for the 
purpose of cell counts (Section 2.2.6). The remaining 480 µl of parasite suspension was centrifuged 
one last time for 30 seconds at 16 606 x g at 4 °C, the supernatant removed, and the pellet 
resuspended in cold lysis solution (10 mM Tris, pH 7.4). The parasite cells were then lysed by 
trituration (~20x) through a 25-guage needle. The lysed suspension was then centrifuged 3 times for 
30 min at 16 606 x g at 4 °C, each time transferring the supernatant to a new centrifuge tube and 
discarding the pellet. The lysate was stored at -20 °C until used for experiments. 
2.2.7 Cell Counts for lysate preparation 
The 50x dilution of the parasite cells before lysis was used to determine the number of trophozoites 
by manually counting them on a Neubauer hemocytometer at a 100x magnification under a light 
microscope to determine the cell counts in cells/ml.  
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2.2.8 Custom preparation of Pantothenate-free media 
Since standard commercially available media contains 1 µM pantothenate, and pantothenate free 
complete media was needed for experiments where pantothenate had to be excluded, two sources 
of pantothenate free media were used for experiments. First, pantothenate free complete media was 
prepared in house by using component information and concentrations of RPMI-1640 media 
available from the Sigma-Aldrich website [6]. A 50x RPMI-1640 amino acid mix was commercially 
available which was used, but further, stocks were made up of the other components: (1) a 20x 
inorganic salt stock containing calcium citrate (8.47 mM), magnesium sulfate (8.12 mM), potassium 
chloride (107.31 mM), sodium chloride (2.053 M), and sodium phosphate dibasic (112.71 mM), (2) 
a 2500x vitamin mix containing D-biotin (2.05 mM), choline chloride (53.72 mM), folic acid (5.66 mM), 
myo-inositol (485.68 mM), niacinamide (20.47 mM), p-aminobenzoic acid (18.23 mM), pyridoxine 
(12.16 mM), riboflavin (1.33 mM), thiamine (7.41 mM), and vitamin B12 (first made up as a 250 000x 
stock and then added to the mixture) (9.00 nM), and separate stocks of (3) D-glucose (22.2 mM), (4) 
glutathione (500x, 1.63 mM), (5) phenol red dissolved in ethanol (250x, 3.52 mM), and (6) L-
glutamine (250x, 513.21 mM). While most of the stocks could be stored at 4 °C and reused whenever 
fresh media was made, glutathione and L-glutamine stocks had to be made up on the day of the 
experiment. Once all the stocks were added together it was supplemented with 25 mM HEPES, 
23.81 mM sodium bicarbonate, 11.1 mM glucose, 200 µM hypoxanthine (dissolved in 0.5M NaOH), 
24 µg/ml gentamycin and 0.6% (m/v) Albumax II serum, and the pH adjusted to 7.4, after which the 
pan-free media was filtered with a 0.2µ syringe filter under sterile conditions and stored at 4 °C till 
needed. 
Later we sourced commercially available custom-made pantothenate free media (Custom RPMI 
medium 1640, without pantothenate, with Glutamax) from AthenaES (USA). This media did not 
require the additional addition of L-glutamine, since it contains Glutamax. 
2.2.9 P. falciparum survival without pantothenate present 
Parasites were cultured as described in section 2.2.2. Once parasites were in the synchronized ring 
stage, 5 ml cultures in 60 ml culture flasks with 2% hematocrit and 1% parasitemia were maintained 
in custom made pantothenate free RPMI-1640 media supplemented with 25 mM HEPES, 23.81 mM 
sodium bicarbonate, 11.1 mM glucose, 200 µM hypoxanthine (dissolved in 0.5M NaOH), 24 µg/ml 
gentamycin and 0.6% m/v Albumax II serum, with pH 7.4 (here on called Pan-free complete media). 
Infected erythrocytes (2% hematocrit, 1% parasitemia) in Pan-free complete media supplemented 
with 1 µM pantothenate were used as a control to estimate the growth pattern when the parasites 
were growing under normal conditions. These cultures were also gassed with a low oxygen gas 
mixture (1% oxygen, 3% carbon dioxide, 96% nitrogen) and incubated at 37 °C on a rotary shaker 
(50 rpm) to encourage synchronous cell culture growth. The media in these cultures were changed 
every day (Ssection 2.2.2) for 8 days, and each day a blood slide made and parasitemia determined 
(section 2.2.4). In addition, an aliquot was taken and frozen at -20 °C for a SYBR Safe and Malstat 
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assay analysis (sections 2.2.8 and 2.2.9). The experiment was performed twice as separate 
experiments each performed in triplicate.  
2.2.10 P. falciparum growth assays for minimum pantothenate requirement 
Parasites were cultured as described in section 2.2.2.  Once parasites were in the ring stage, the 
assay was set up in a sterile 96-well cell culture plate with a 2% hematocrit and 1% parasitemia in 
Pan-free complete media. A two-times serial dilution of the pantothenate-containing wells was done 
in triplicate, with the final pantothenate concentration ranging between 1 µM and 1.9 pM, with a final 
volume of 200 µl per well. Infected erythrocytes (2% hematocrit, 1% parasitemia) in Pan-free 
complete media supplemented with 1 µM pantothenate were used as a control to estimate of 100% 
parasite growth. Uninfected erythrocytes with a hematocrit of 2% in RPMI complete media, as well 
as Plasmodium infected erythrocytes with 1 µM chloroquine in RPMI complete media were both used 
as a negative control (to subtract background), with the uninfected erythrocytes control serving as a 
check that the parasites were not becoming chloroquine resistant. In addition to this, parasite 
infected erythrocytes with a hematocrit of 2% and 1% parasitemia in Pan-free complete media 
served as an extra control to confirm whether the parasites actually died within the incubation period 
with no pantothenate present. Wells not being used were filled with 200 µl media. These plates were 
then incubated at 37 °C for 2 parasite life-cycles (96 hours) inside an air-tight desiccator that had 
been flushed with a low oxygen gas mixture (1% oxygen, 3% carbon dioxide, 96% nitrogen). These 
assays were then analyzed by means of the SYBR Safe assay (see section 2.2.12) as well as the 
Malstat assay (See section 2.2.13). 
2.2.11 SYBR Safe assay  
For all SYBR Safe assay analyses used to determine parasite viability, 100 µl SYBR Safe solution, 
which consists of 2 µl SYBR Safe in 10 ml lysis buffer (20 mM Tris, 5 mM EDTA, 0.008% (m/v) 
saponin, 0.08% (v/v) TritonX-100, pH 7.5), was aliquoted into each well of a black 96-well plate. 
From the original assay 96-well plate, 100 µl of the homogenous sample of each well was transferred 
to the SYBR Safe solution and mixed gently. Fluorescence was measured on a Varioskan multimode 
reader (Thermo Fisher Scientific Inc.) with excitation and emission wavelengths at 490 nm and 520 
nm, respectively. 
2.2.12 Malstat assay analysis 
Before the Malstat analysis was done, culture samples were subjected to freeze-thaw cycles (3x) to 
lyse all the red blood cells. Thereafter, to a clear 96-well plate, 100 µl Malstat reagent (0.2% (v/v) 
Triton X-100, 220 mM lactic acid, 41.9 mM Tris, 0.17 mM 3-acetylpyridine adenine dinucleotide 
(APAD), pH 9.0), 25µl NBT/PES solution (1.96 mM nitro blue tetrazolium, 0.24 mM phenazine 
ethosulphate) and 15 µl homogenous blood culture sample were added. Once mixed, the plates 
were incubated in the dark (the reagents are light sensitive) for 30 min before they were 
spectrophotometrically analyzed at 620 nm with a Varioskan multimode reader (Thermo Fisher 
Scientific Inc.). 
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2.2.13 Data analysis for Malstat and SYBR Safe assays 
For SYBR Safe and Malstat assays data were collected in triplicate. The average of the blank was 
thus subtracted from all the data points and the average of each point plotted as a percentage of 
total growth (compared to the 100% control). Two repeats were done of each experiment, and error 
calculated (standard error of the mean) by the standard deviation of the average of the repeats, 
divided by the number of repeats (in this case 2). 
2.2.14 Absorption profile of N-PE-α-Me-PanAm 
The absorption profile of 500 µM N-PE-α-Me-PanAm (dissolved in water) was recorded between 
200 and 400 nm on a Varioskan spectrophotometer. 
2.2.15 Biosynthesis of CoA analogues with P. falciparum cell lysate 
Reaction mixtures (250 µl final volume) containing P. falciparum cell lysates (section 2.2.6) were 
used to carry out the conversion of the N-PE-α-Me-PanAm, the substrate, to its corresponding CoA 
antimetabolites. Cell lysate stored in 10 mM HEPES buffer (pH 7.6) had a concentration of ~1.975 x 
109 cells/ml and lysates stored in 10 mM Tris (pH 7.6) had a concentration of ~3.128 x 109 cells/ml. 
The reactions consisted of 16.5 mM ATP (pH 7), 10 mM MgCl2, 125 µl cell lysate in HEPES or Tris 
buffer, 50 mM HEPES or Tris (pH 7.6) and 5 mM α-Me-N-PE-PanAm. The reactions were incubated 
overnight at 37 °C before analyzing via HPLC (See section 2.2.21.2). 
2.2.16 N-PE-α-Me-PanAm metabolism in P. falciparum cultures 
P. falciparum cultures (8 x 50 ml) were cultured to a parasitemia of 10-15% (section 2.2.2) and 
treated in the ring stage with 52 nM of the racemic mixture of N-PE-α-Me-PanAm. Another set of P. 
falciparum cultures (8 x 50 ml) were cultured with the same parasitemia, however these cultures 
were not treated with N-PE-α-Me-PanAm, but served as a control. All cultures were incubated for 24 
hours, after which the parasites were isolated and lysed (section 2.2.6). The lysate was then heated 
to 95 °C for 15 min and kept on ice for 5 min before centrifugation at 16 606 x g to pellet the proteins 
and enzymes. The supernatant was then analyzed by LC-MS (see section 2.2.20 for conditions). 
2.2.17 Conversion of N-PE-α-Me-PanAm to antimetabolites by bacterial enzymes for 
LC-MS method validation 
An enzymatic reaction, using N-PE-α-Me-PanAm as a substrate, was set up using active isolated 
bacterial enzymes from S. aureus and E. coli. The reactions, with a volume of 250 µl each, were set 
up by adding 60 mM HEPES (pH 8.0), 16.5 mM ATP, 10 mM MgCl2, and 10 mM N-PE-α-Me-PanAm 
followed by the addition of 51 μg of each enzyme, SaPanK, EcPPAT and EcDPCK. The reaction 
mixtures were incubated for 24 hours at 37 °C after which they were diluted with 250 µl 10 mM 
ammonium acetate, pH 6.0. Proteins were then removed by heat precipitation at 95 °C for 5 min, 
followed by 2 x 30 min centrifugation at 16 606 x g to pellet the proteins and the supernatant 
transferred to a new centrifuge tube each time. The supernatant was then analyzed by LC-MS (see 
section 2.2.20 for conditions). 
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2.2.18 Biosynthesis of CoA and intermediates with P. falciparum cell lysate for LC-MS 
analysis 
To check whether the P. falciparum lysate enzymes were active, biosynthetic reactions were set up 
in lysates prepared in Tris and HEPES buffer respectively using CoA biosynthesis natural substrates, 
pantetheine and dephosphoCoA. Pantetheine was prepared by reducing, 25 mM pantethine 
(commercially available disulfide of pantetheine) in 37.5 mM TCEP for 10 min at room temperature. 
5 mM substrate (either pantetheine or dephosphoCoA) was then incubated in the presence of 16.5 
mM ATP, 10 mM MgCl2, 125 µl cell lysate in HEPES (10 mM, pH 7.6) and 2.5 mM HEPES buffer 
(pH 7.6) in a final volume of 250 µl. Another set of reactions were set up, replacing the cell lysates 
stored in HEPES with the lysate stored in 10 mM Tris (pH 7.6) and the HEPES buffer with 2.5 mM 
Tris (pH 7.6). All the reactions were incubated for 24 hours at 37 °C after which proteins were then 
removed by heat precipitation at 95 °C for 5 min, followed by 2 x 30 min centrifugation at 16 606 x g 
to pellet the proteins and the supernatant carried over to a new centrifuge tube each time. The 
supernatant was then analyzed by LC-MS (see section 2.2.19 for conditions). 
2.2.19 LC-MS conditions for analysis of biosynthesized CoA analogues 
LC-MS analysis was performed at CAF (Stellenbosch University) as described previously [7]. LC-
MS analysis was performed with 10 mM ammonium acetate, pH 6.5 (solution A) and 1% formic acid 
in acetonitrile (solution B) on a Waters Synapt G2 system on a Waters HSS C18 column (2.1 x 150 
mm) with a flow rate of 0.3 ml/min. The column was first equilibrated in 98% solution A and 2% 
solution B. This was followed by elution with 98% solution A (0-1 min, isocratic), a linear gradient 
increasing solution B to 20% (1-10 min), a linear gradient increasing solution B to 100% (10-15 min), 
an isocratic elution at 100% solution B (15-16 min) and a linear gradient returning to 98% solution A 
(16-20 min, isocratic). Electrospray Ionization (ESI) was applied in the positive mode and negative 
modes at a capillary voltage of 2.5 kV, cone voltage of 15 V, desolvation temperature of 275 °C and 
desolvation gas setting of 650 L/h, with the remaining settings optimized for optimal sensitivity. The 
instrument was calibrated with sodium formate, and leucine enkaphelin was used as lock mass for 
accurate mass determinations. The MS acquisition method consisted of a low energy function at a 
trap voltage of 6 V and a high energy function where the trap collision energy was ramped from 15 
to 60 V to generate fragmentation data (MSE).  
2.2.20 Derivatization of thiol containing substrates and products with CPM 
Cell lysate reactions prepared as in section 2.2.19 were derivatized with 7-Diethylamino-3-(4'-
maleimidylphenyl)-4-methylcoumarin (CPM) before HPLC analysis. The reactions were stopped 
after 24 hour incubation step by heat precipitation of the P. falciparum cell lysate proteins at 95 °C 
for 5 min, followed by centrifugation twice for 30 min at 16 606 x g. The supernatant was then filtered 
with 0.2 gauge syringe filter and the supernatant CPM derivatized. This was done by setting up 140 
µl derivatization reactions, containing 44.62 µl lysate reaction supernatant, 67.6 nM TCEP, 3.62 mM 
Tris (pH 7.6), 1.45 mM, MgCl2 and 1.45 mM KCl. Subsequently, reactions were allowed to incubate 
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for 10 min at room temperature before the addition of 4.5 nM CPM. This mixture was incubated 
overnight at room temperature before analysis via HPLC. 
2.2.21 HPLC analyses 
2.2.21.1 HPLC analysis of CPM derived CoA metabolites and intermediates 
Analysis of CPM derivatized CoA analogues and intermediates was done using a previously 
published method [2]. Briefly, once the metabolites were labelled with CPM (section 2.2.20), they 
were injected (5 µl injection) onto an Agilent Series 1200 HPLC system on a 5µM SUPELCOSIL™ 
LC-DP column (4.6 x 250 mm) with a flow rate of 1.0 ml/min. HPLC analyses were performed with 
50 mM potassium phosphate (pH 6.8) (solution A), 60% acetonitrile (solution B) and 100% 
acetonitrile (solution C). The column was first equilibrated in 50% solution A and 50% solution B. 
This was followed by elution with 50% solution A and 50% solution B  (0-5 min, isocratic), a linear 
gradient increasing solution B to 60% (5-25 min), a linear gradient increasing solution C to 60%, 
keeping solution A at 40% (25-26 min), an isocratic elution at 40% solution A/60% solution C (26-33 
min) and a linear elution increasing solution C to 90%, with solution A decreasing to 10% (33-36 
min). This was followed by an isocratic elution at 10% solution A/90% solution C (36-42 min), a linear 
gradient returning to 50% solution A/50% solution C (42-52 min), ending with an isocratic elution at 
50% solution A/50% solution C (52-57 min).   
2.2.21.2 HPLC analysis of the N-PE-α-Me-PanAm and its CoA antimetabolites 
Analysis of N-PE-α-Me-PanAm and its corresponding CoA antimetabolites was done using the 
following method: samples were injected (35 µl injection) onto an Agilent Series 1100 HPLC system 
on a Phenomenix Luna C18 100A 250 x 4.60 mm column with a flow rate of 1.0 ml/min. HPLC 
analysis was performed with 10 mM ammonium acetate buffer, pH 5.5 (solution A) and acetonitrile 
(solution B). The column was first equilibrated in 95% solution A and 5% solution B. This was 
followed by elution with 95% solution A (0-5 min, isocratic), a linear gradient increasing solution B to 
20% (5-6 min), a linear gradient increasing solution B to 40% (6-10min), an isocratic elution at 40% 
solution B and 60% solution A (10-15min) a linear gradient increasing solution B to 60% (15-16min), 
and an isocratic elution at solution B to 60% (16-20 min). UV detection of products was done at 220 
nm and 254 nm. 
2.2.22 Synthesis of tricyclic methylthiophenyl propanamide 
2.2.22.1 Compound 1 
2-Chloro-3-pyrimadinecarbonitrile (0.660 g, 4.76 mmol) was dissolved in 10 ml 
ethanol, followed by the addition of 5 equivalents of hydrazine hydrate (1.49 ml, 23.8 
mmol). This was refluxed overnight under nitrogen gas, resulting in a bright yellow 
reaction mixture which was concentrated in vacuo. Thereafter, 5 ml water was added 
and the resulting mixture was stirred at room temperature for 1 hour. The suspension 
was then filtered and the filtrate dried in vacuo to yield a yellow residue (0.890 g, 66% yield). The 
residue was used in the next step without further purification. 1H NMR (300 MHz, DMSO-d6) δ 11.91 
(1) 
Stellenbosch University  https://scholar.sun.ac.za
36 
 
(s, 1H), 8.33 (dd, J = 4.6, 1.6 Hz, 1H), 8.11 (dd, J = 7.9, 4.6 Hz, 1H), 6.94 (dd, J = 7.9, 4.6 Hz, 1H), 
5.54 (s, 2H), 3.41-3.17 (m, 2H). 1H NMR is consistent with literature data [8]. 
2.2.21.2 Compound 2 
Compound 1 (0.948 g, 5.56 mmol) was dissolved in 8 ml ethanol and 
methyl 4-acetyl-5-oxohexanoate (1.85 ml, 10.6 mmol) was added. The 
mixture was refluxed overnight under nitrogen, resulting in a clear 
orange mixture. After cooling, the mixture was concentrated in vacuo, 
dissolved in ethyl acetate and dried in vacuo again. This was repeated 
three times. The resulting residue was resuspended in 10 ml diethyl ether and the final product 
filtered, and the precipitate washed (3 x 10 ml) with diethyl ether. The final product was obtained in 
49% yield (1.54 g). 1H NMR (300 MHz, chloroform-d) δ 8.91 (dd, J = 4.4, 1.8 Hz 1H), 8.61 (dd, J = 
8.1, 1.8 Hz, 1H), 7.20 (dd, J = 8.1, 4.4 Hz, 1H), 3.74 (s, 3H), 3.24 (dd, J = 9.2, 7.1 Hz, 2H), 3.05 (s, 
3H), 2.81 (s, 3H), 2.66 – 2.61 (m, 2H). 1H NMR is consistent with literature data [8]. 
2.2.22.3 Compound 3 
Compound 2 (0.050 g, 0.18 mmol) was mixed with 3 equivalents 1M 
aq. NaOH (1.48 ml) and 5 ml tetrahydrofuran (THF). This was left to stir 
overnight at room temperature. After the reaction was deemed 
complete by TLC (5:1 ethyl acetate:hexane), the THF was removed in 
vacuo and the remaining residue dissolved in 5 ml water. It was then washed three times in a 
separating funnel, with 5 ml ethyl acetate and the product freeze dried to yield a white powder (0.305 
g; >99% yield). 1H NMR (300 MHz, D2O) δ 8.57 (dd, J = 4.5, 0.9 Hz, 1H), 8.13 (d, J = 8.1 Hz, 1H), 
7.11 (dd, J = 8.1, 4.5 Hz, 1H), 2.92 (dd, J = 9.8, 6.9 Hz, 2H), 2.67 (s, 3H), 2.55 (s, 3H), 2.37 (dd, J = 
9.7, 6.9 Hz, 2H). 1H NMR is consistent with literature data [8]. 
2.2.22.4 Compound 5 
Method 1:  
Compound 3 (0.100 g, 0.370 mmol) was added to 2.1 equivalents of 
thionyl chloride (0.059 ml, 0.41 mmol) in 3 ml dimethylformamide (DMF). 
This mixture was stirred overnight while heating from room temperature 
to 70 °C under nitrogen. Product formation was determined by TLC 
(16:2:1:1 ethyl acetate:butanol:acetic acid:water, Rf value 0.45), however no visible change was 
seen on TLC. It was thus followed by the addition of 2 equivalents of triethylamine (0.061 ml, 0.40 
mmol) and stirred it at room temperature for 4 hours under nitrogen, after which the DMF and excess 
amines were removed in vacuo, resulting in a residue (0.152 g, <99% yield).  
Method 2: 
Compound 3 (0.150 g, 0.560 mmol) mixed with 12.5 equivalents of thionyl chloride (0.350 ml). This 
was cooled to 0 °C, after which 2.5 ml dry DMF was added drop-wise and the mixture stirred for 5 
min after which the reaction was refluxed overnight. Product formation was determined by TLC (5% 
methanol/DCM, Rf value 0.66). The reaction was deemed complete when no starting reagent was 
visible on TLC. The DMF and excess thionyl chloride were removed in vacuo, followed by co-
(2) 
(3) 
(5) 
(2) 
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evaporation with 10 ml toluene and 10 ml diethyl ether, respectively. This resulted in a brown residue 
(0.248 g, <99% yield). No further purification was done and the resulting residue was used as is in 
the next step. 
 
2.2.22.5 Compound 4 
Method 1: HBTU coupling  
Compound 4 (0.153 g, 0.106 mmol) was added to 1.3 ml dry 
DMF to form a suspension. Subsequently, 2 equivalents 
N,N,N′,N′-tetramethyl-O-(1H-benzotriazol-1-yl)uronium 
hexafluorophosphate (HBTU) (0.074 g, 0.21 mmol) and 1.5 
equivalents (31 µl, 0.16 mmol) triethylamine were added and allowed to stir for 5 min. Thereafter, 
3.6 equivalents 3-(methylthio)aniline (65 µl, 0.38 mmol) were added to the reaction mixture and 
stirred for 4 hours at room temperature under nitrogen gas. The reaction was monitored by TLC (5% 
methanol/ dichloromethane) and subsequently the reaction mixture was concentrated in vacuo 
(0.980 g crude). The resulting residue was purified on a silica column (5 % 
methanol/dichloromethane, 20 % methanol/dichloromethane) and the fractions analyzed on TLCs (5 
% methanol/dichloromethane). The desired fractions (Rf value 0.41) were pooled and dried (<5 mg, 
therefore enough to do NMR analysis but not to pursue further). 1H NMR (300 MHz, DMSO-d6) δ 
9.99 (s, 1H), 8.81 (dd, J = 3.2 Hz 1H), 8.57 (ddd, J = 8.1, 1.8, 0.6 Hz, 1H), 7.53 (t, J = 1.8 Hz, 1H), 
7.31-7.28 (m, 1H), 7.24 – 7.19 (m, 2H), 6.91 (ddd, J = 7.7, 1.8, 1.1 Hz, 1H), 3.32 – 3.02 (m, 4H), 
2.92 (s, 3H), 2.73 (s, 3H), 2.68 – 2.57 (m, 2H), 2.42 (s, 1H). 1H NMR is consistent with literature data 
[8]. 
In an alternative work-up, after the reaction was complete, the resulting residue was dissolved in 10 
ml ethyl acetate and washed with 5 %(m/v) citric acid (2 x 5 ml), 1 M NaHCO3 (2 x 5 ml), and brine 
(1 x 5 ml). The organic layer was dried over NaSO4, filtered and concentrated in vacuo. The crude 
mixture was purified by flash column chromatography (10% ethyl acetate/dichloromethane followed 
by 5 % methanol/dichloromethane). The partially purified product was dried in vacuo to yield a white 
solid (<5 mg). However, NMR spectroscopy indicated this was not the desired product. Unfortunately 
the NMR spectra was inconclusive to identify peaks present. 
 
Method 2: EDC Coupling 
3-(Methylthio)aniline (21 µl, 0.17 mmol) was added to 2.5 ml dry DMF and this mixture cooled to 0 
°C. N,N-diisopropylethylamine (DIPEA) (30 µl, 0.17 mmol) was added dropwise to this cooled 
mixture as not to raise the temperature above 5 °C. Hydroxybenzotriazole (HOBt) (0.005 g, 3 nmol), 
compound 3 (0.050 g, 0.19 mmol) and N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide 
hydrochloride (EDC) (0.026 g, 0.68 mmol) were added. This mixture was then stirred overnight at 
room temperature. Product formation was determined by TLC (5% methanol/dichloromethane, Rf 
(4) 
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value 0.59) but this showed the coupling to be unsuccessful and thus the method was not pursued 
further. 
 
Method 3: B(OCH2CF3)3 amidation 
B2O3 (12.0 g, 172 mmol) and 2,2,2-trifluoroethanol (25 ml, 347 mmol) were refluxed overnight, after 
which the mixture was filtered to remove excess boric anhydride and the filtrate purified by distillation 
(80 °C under a vacuum). The resulting B(OCH2CF3)3 could then be stored at room temperature for 
up to 4 months. 
Next, the amidation reaction was performed by refluxing the compound 3 (0.104 g, 0.385 mmol) with 
2 equivalents of B(OCH2CF3)3 (0.048 g, 0.77 mmol), 1 equivalent  3-(methylthio)alinine (5 µl, 0.4 
mmol) and 2 ml acetonitrile overnight. After completion of the reaction, the product was diluted with 
ethyl acetate (3 ml) and water (0.5 ml). Amberlyst A-26(OH), Amberlyst 15 and Amberlite IRA743 
resins were added (50 ml dry volume of each). This resulting slurry was stirred for 30 min and 
magnesium sulphate added to remove excess water. The resulting solid was washed 3 times with 5 
ml ethyl acetate and filtered, then the filtrate concentrated in vacuo. TLCs were run in 5% 
methanol/dichloromethane and 1:9 hexane/ethylacetate but many impurities were present and 
suggested co-elution if purified on a silica column, thus the method was abandoned. 
 
Method 4: Amidation using acid chloride derivative 
Compound 4 (0.062 mg, 0.22 mmol) was dissolved in 2.5 ml dichloromethane (DCM) and divided 
into 4 round bottom flasks. To each flask, 4 equivalents of the amine (0.56 mmol) in 500 µl 4-picoline 
(5.14 mmol) were added separately to each flask. The amines coupled were 3-(methylthio)aniline, 
3-fluoroaniline, 3-(trifluoromethyl)aniline and 4’-aminoacetanilide. After stirring for 4 hours under 
nitrogen gas, the mixtures were concentrate in vacuo. The reactions were followed by TLC (5% 
methanol/dichloromethane) to determine which reaction was the most successful. The reaction of 3-
fluoroaniline was chosen for purification by silica plug using 5%-10% methanol/DCM to yield a 
partially purified product (0.630 g – not dry). 1H NMR (400 MHz, DMSO-d6) showed all peaks present 
that were present in the NMR spectrum of the HBTU coupling product, however many impurities 
resulted in additional peaks. 
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Chapter 3: Results and Discussion 
 
3.1 Introduction 
Most of the efforts to curb the malaria-caused death toll are aimed at prevention. However treatment 
of this disease is still critical, especially now that Plasmodium has exhibited resistance to all current 
drugs used for the treatment of malaria [1]. New antimalarial drugs with novel modes of action are 
therefore still desperately needed. In order to develop new drugs, alternative drug targets need to 
be identified. This is a challenge because limited knowledge is available about the metabolic 
processes of Plasmodium, and thus even an increased knowledge of such processes and parasite 
biology could aid in the discovery of novel drug targets. 
The CoA biosynthetic pathway is one of the pathways which is crucial to the survival of the parasite 
[2] and many attempts are currently being made to target this pathway [3-7]. Presently the most 
potent inhibitors of the CoA biosynthesis pathway are PanAms [4], however the specific mode of 
action of these compounds are still unknown. The purpose of this project was therefore to better 
understand parasite biology in terms of CoA biosynthesis and to pinpoint how biological processes 
are affected within the parasite. This will aid future studies to determine the exact mode of action for 
the PanAms.  
3.2 Results 
3.2.1 Establishing the minimum extracellular pantothenate needed for parasite 
survival  
PanAms target CoA biosynthesis and/or utilization in P. falciparum, however the critical amount of 
CoA needed for parasite survival is still unknown. By determining the critical amount of CoA the 
parasite needs for survival, we can determine the threshold needed for PanAms to interfere with 
CoA biosynthesis. However this is not an easy determination to make since parasites obtain CoA 
from pantothenate received from the host red blood cell that in turn obtains pantothenate from 
extracellular sources. Based on current data, the amount of pantothenate available to P. falciparum 
in the host blood stream is ~2.5 µM [8]. P. falciparum is cultured in the presence of 1 µM 
pantothenate, which correlates well with levels available in the human host. These culture conditions 
are similar to in vivo conditions, thus allowing us to perform experiments to determine the minimum 
required pantothenate needed for the survival of blood stage P. falciparum parasites.  
3.2.1.1 Parasite survival without pantothenate present 
In order to determine the minimum amount of pantothenate needed for survival, the first objective 
was to determine how long P. falciparum 3D7 parasites cultured in the laboratory could survive 
without pantothenate present in the culturing media, in order to determine the timeframe for the 
pantothenate requirement assay. For this purpose the parasites were cultured in pantothenate-free 
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media. Since all commercially available RPMI-1640 media contains pantothenate, we prepared 
RPMI-media without any pantothenate present in-house. To achieve this, the component information 
of RPMI-1640 media available from Sigma-Aldrich was used as reference [9]. See section 2.2.8 for 
details. 
 
After the successful preparation of custom-made pantothenate-free media (Pan-free complete 
media), P. falciparum parasites were cultured in this media for six days to observe their ability to 
grow without pantothenate present. Parasite survival was determined by using a Malstat assay which 
measures a colourimetric change caused by the production of pyruvate from lactate by lactate 
dehydrogenase enzymes, which leads to the reduction of NTB, which causes a colour change from 
yellow to blue.  Control experiments were also performed in parallel. The first control was P. 
falciparum parasites cultivated in Pan-free complete media supplemented with 1 M pantothenate 
(comparable to commercial complete RPMI-media) that was used to determine normal parasite 
growth. In addition a culture containing 1 M chloroquine was used as positive control for no parasite 
growth. 
 
Surprisingly, all cultures (including the negative control that contained sufficient pantothenate) 
showed a decline in parasite growth over six days (Figure 3.1A). We therefore concluded that the 
quality of some of the components sourced for media preparation was not suitable for P. falciparum 
in vitro culture. As an alternative, commercial Pan-free media was therefore sourced from an 
American-based company, AthenaES, which had the same components as the RPMI-1640 media, 
except for pantothenate. This media was used to repeat the above experiment of the controls to 
determine whether the media prepared in-house was the problem. Here, the controls were incubated 
for seven days after which the Malstat assay was used to determine parasite survival of each control 
(Figure 3.1B) 
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Figure 3.1:  (A) Parasite survival assay controls over 6 days in a 96-well microtiter plate, 
determined by use of a Malstat assay. The symbols in red indicate parasite -infected 
erythrocytes in complete media, the symbols in blue indicate the negative control where 
parasite-infected erythrocytes are cultured in media containing chloroquine, and the 
yellow symbols indicate parasite-infected erythrocytes cultures in Pan-free media. Data 
are the average of one experiment performed in duplicate with errors bars indicating SD. 
(B) Malstat Assay determination of parasite survival (assay controls) of parasites 
cultured in a 96-well microtiter plate, in commercially bought custom made Pan-free 
media (yellow bar) and complete media (red bar) after a period of seven days. Data are 
the average of one experiment performed in t riplicate with errors bars indicating SD.  
 
In this experiment the iRBCs in complete media showed the highest growth (assumed to be 100% 
growth) while the iRBCs with chloroquine in complete media had little to no growth and could be 
subtracted as a blank. This is an indication that under normal culture condition in the commercially 
sourced media, parasites proliferate normally. However, the iRBCs were still showing >90% growth 
even after 7 days in Pan-free complete media, which indicated that there were alternative factors 
that interfered with the assay. Confident that the commercially bought media was of good quality, we 
set out to determine how long our parasites could survive in Pan-free complete media. Consequently, 
5 ml P. falciparum cultures were cultivated over time, in both Pan-free and complete media to 
determine parasite survival in a pantothenate-free environment in comparison to when there was 1 
M pantothenate present.  Three methods were used to determine parasite survival in order to 
compare the results from different assays: 1) Giemsa-stained blood slides which allows manual 
counting of viable parasites, 2) a SYBR Safe assay which relies on SYBR safe dye to fluorescently 
A B 
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stain parasite DNA for fluorometric measurement, and 3) the Malstat assay that measures lactate 
dehydrogenase activity present in parasites.  
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Figure 3.2: Parasite survival determined over time in Pan-free media using three different 
methods, starting with a 2% hematocrit and 1% parasitemia. Culture samples analyzed 
by (A) manual counting of cells on a blood slide, (B) SYBR Safe assay measuring 
fluorescence of SYBR safe dyed parasite DNA, and (C) Malstat assay measuring the 
colourimetric change of NTB from yellow to blue. Red c ircles indicate parasite-infected 
erythrocytes cultures in RPMI complete media and yellow symbols indicate parasite -
infected erythrocytes cultures in Pan-free media. Data are the average of two 
independent experiments performed in triplicate with errors ba rs indicating range/2.  
A 
B 
C 
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Although the different methods of data collection resulted in different curve shapes (Figure 3.2), there 
is still a general correlation for parasite survival between the different methods used to determine 
survival. All cultures were started with a 1% parasitemia for both cultures in Pan-free complete media 
and RPMI-complete media, however the parasites in the complete media proliferated at a much 
faster rate than those in the Pan-free media as expected. All three assays indicated maximum 
parasitemia in the RPMI-complete media between days 5 and 6, before rapidly decreasing again. 
For the parasites grown in Pan-free complete media, the parasitemia first increased slightly after ~3-
4 days, before decreasing again, reaching zero after eight days.  
 
Other groups have performed similar experiments in Pan-free complete media. Saliba et. al used a 
hypoxanthine assay in order to determine parasite survival in the absence of pantothenate [1]. This 
assay measures the level of radioactivity of the [3H]-hypoxanthine incorporated into nucleic acids of 
the parasites when they proliferate, therefore the higher the level of radioactivity, the more parasites 
are present. They performed the experiments over 96 hours in 96-well microtiter plates at 1% 
parasitemia and 1% hematocrit, in RPMI-1640 media that was devoid of vitamins, supplemented 
with 25 mM sodium bicarbonate, 25 mM HEPES, 2.4 µM hypoxanthine, 24 µg/mL gentamicin, 11 
mM glucose and 6 g/L Albumax serum. After the 96 hour incubation without pantothenate, the 
parasite proliferation was determined by measuring the [3H]hypoxanthine incorporation. In these 
experiments, the parasites only survived approximately 48 hours in the absence of pantothenate. 
Another study investigated the P. falciparum pantothenate transporter and its importance to parasite 
survival [10].  P. falciparum parasites were cultured in the absence of pantothenate, starting with a 
2% hematocrit and a 1% parasitemia and parasite survival was determined daily by manual counting 
of parasitemia. In this study, the parasites only survived for three days in the absence of 
pantothenate. It is evident in our results, even when using a variety of assay methods, that the 
apparent time period that parasites survive without pantothenate is much longer than found in these 
studies. 
 
 
3.2.1.2 The minimum amount of extracellular pantothenate necessary for P. 
falciparum survival 
In order to determine the minimum extracellular pantothenate needed by parasites to survive, assays 
were set up in a 96-well microtiter plate, where parasites were incubated in varying concentrations 
of pantothenate, between 1 µM (the concentration in standard RPMI-1640 culture media) and 1.907 
ρM by means of a two-fold serial dilution. These plates were then incubated for 96 hours before 
analyzing the parasite survival at each concentration by means of the SYBR Safe assay.  
The growth seemed to stay constant at 70% in media containing between 1 µM and 7.9 nM 
pantothenate compared to standard RPMI-complete media used for culturing, before the parasite 
survival started to be affected (Figure 3.3). From 7.9 nM, the parasite survival drops, however ~25% 
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of the parasites still survived at very low concentrations of pantothenate present. These results align 
with survival experiments in section 3.2.1 where parasites are able to survive on no or very low levels 
of pantothenate present after 96 hours.  
log Pantothenate Concentration (µM)
0.000001 0.00001 0.0001 0.001 0.01 0.1 1
P
a
ra
s
it
e
 S
u
rv
iv
a
l (
%
)
10
20
30
40
50
60
70
80
 
Figure 3.3: Parasite survival in varying concentrations of pantothenate after 96 hours. A 
serial dilution was done of the pantothenate between a concentration of 1 µM and 
1.907ρM. Data were normalized to RPMI-complete media as which was considered 100% 
growth. Data are the average of one experiment performed in triplicate with errors bars 
indicating SD. 
 
 
3.2.1.3 The influence of Mycoplasma infections on parasite survival 
Since P. falciparum parasites cultured were found to survive for 8 days compared to the 3-4 days 
reported in previous studies [1, 10], we investigated possible causes for the prolonged survival 
without pantothenate. One option was to test cultures for Mycoplasma infection. Mycoplasma 
infections have become a common problem in P. falciparum culture procedures. It is also known that 
Mycoplasmas can lead to various unwanted effects in eukaryotic cell cultures like impaired growth 
and abnormalities in various biochemical processes [11]. Therefore we tested our cultures for the 
presence of Mycoplasmas by using a routine PCR method for this purpose. Briefly, a PCR is 
performed using media that was incubated with the parasites for 24 hours, along with 9 primers, 6 
forward and 3 reverse primers, specific for a broad range of Mycoplasma species.   
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Figure 3.4: Detection of Mycoplasma in P. falciparum  cultures before and after treatment 
with Mycoplasma Removal Agent. (A) PCR products run on a 1% agarose gel, showing a 
positive test for the presence of Mycoplasma from cultures. The lanes are as follows: (1) 
Universal Ladder (KAPA), (2) negative control (no enzyme), (3) negative control (no 
template), (4) positive control (50x dilution Mycoplasma MS02 DNA), (5) culture 
supernatant, (6) freezer stocks culture supernatant.  (B) PCR run on a 1% agarose gel, 
testing negative for the presence of Mycoplasma from cultures after treatment with the 
Mycoplasma Removal Agent. The lanes are as follows (1) Universal Ladder, (2) positive 
control (50x dilution Mycoplasma MS02 DNA, (3) negative control (no enzyme), (4) 
negative control (no template), (5) treated culture supernatant, (6) treated freezer stocks 
culture supernatant, (7) RPMI-1460 media used, (8) fresh bottle of RPMI-1640 media 
without Albumax II serum, (9) Fresh RPMI-1640 media containing Albumax II serum, (10) 
supernatant from washed blood stock.  
 
The PCR (Figure 3.4A) test was positive for the presence of Mycoplasmas in both the cultures (one 
of which was recently started from freezer stocks and the other which had already been cultured for 
a few weeks) with at band 700 bp comparing well with the positive control, MS02. This indicated that 
the Mycoplasma infection was present not only in the actively growing cultures but in the freezer 
stocks too. Consequently, a culture was treated with Mycoplasma Removal Agent (MRA) for a period 
of five days before the PCR was repeated and amplified DNA run on a 1% agar gel containing Nancy-
520 fluorescent DNA stain. From the results (Figure 3.4B), it can be concluded that the cultures were 
Mycoplasma free. In addition, all the components used to culture, such as the RPMI-1640 media, 
the Albumax-II serum, and the washed human erythrocytes, were also tested and confirmed to be 
Mycoplasma free. 
 
After the removal of Mycoplasma, the survival experiment for P. falciparum parasite in Pan-free 
complete media as well as the experiment to ascertain the minimum amount of pantothenate 
required for survival were repeated, however the results were inconclusive. Unfortunately, within the 
timeframe allowed for this project, we were unable to perform either of the experiments again to 
allow conclusions to be drawn and these experiments need to be repeated in future work.  
A B 
700 bp 
1   2   3   4   5   6 
700 bp 
1    2    3   4    5    6    7     8    9   10 
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3.2.2 Metabolism of PanAms by the CoA biosynthetic enzymes of P. 
falciparum  
Although we were unable to establish the minimum requirement for pantothenate in parasites, 
previous experiments have clearly shown that the PanAms have an influence on pantothenate 
metabolism. We wanted to determine whether PanAms could be converted to the corresponding 
CoA antimetabolites by the CoA biosynthetic enzymes present in P. falciparum parasites. Such 
evidence would lend support to the PanAms having a mode of action that is downstream in the 
pathway, and affecting the parasite by either lowering CoA levels (by competitive formation of CoA 
antimetabolites) or by forming CoA antimetabolites that can possibly inhibit downstream processes 
in the parasite. In this study we specifically chose N-PE-α-Me-PanAm which was the most potent 
vanin resistant inhibitor in our laboratory [12]. To determine the fate of this PanAm in the CoA 
biosynthesis pathway (Figure 3.5) we followed two approaches: 1) expose the PanAm to enzymes 
present in parasite lysate prepared from isolated P. falciparum parasites or 2) incubate P. falciparum 
parasites with a non-lethal dose of PanAm after which they can be isolated and lysed for analysis. 
In both these approaches HPLC analysis was used to detect antimetabolite formation. 
  
 
Figure 3.5: The biosynthesis of CoA antimetabolites from a PanAm. The conversion of N-
PE-α-Me-PanAm by the CoA pathway enzymes PanK, PPAT and DPCK is shown, forming 
the antimetabolite intermediates 4’ -phospho-N-PE-α-Me-PanAm, dephospho-N-PE-α-Me-
CoA and N-PE-α-Me-CoA [13] .  
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3.2.2.1 Method development for CoA antimetabolite detection 
3.2.2.1.1 Detection of N-PE-α-Me-PanAm via UV absorbance 
We have various methods available in our laboratory for the detection of PanAms and their 
corresponding metabolites [13-16]. However, most of these methods were used to analyze samples 
that made use of purified CoA biosynthesis enzymes from bacteria and therefore allowed the 
preparation of antimetabolites at high concentrations. Since we do not have the ability to express 
and purify these proteins from P. falciparum, we had to identify which of the HPLC methods available 
would allow for detection of the presumed CoA antimetabolites in parasite in much lower 
concentrations than what is possible when working with purified protein. 
 
First, we wanted to determine at what concentration we would see adequate signal via UV detection 
of N-PE-α-Me-PanAm. The amide bonds present in PanAms usually allow detection at 214 nm [13], 
however the baseline of chromatograms obtained at this wavelength can contain a lot of background 
noise. Since N-PE-α-Me-PanAm has an aromatic group in the phenethylamide moiety of the 
molecule, we also investigated whether UV detection was possible at ~254 nm, the wavelength 
usually used for detection of aromatic compounds. The UV absorption profile of the molecule was 
determined spectrophotometrically to obtain the absorption maxima of the compound. N-PE-α-Me-
PanAm has an absorption maxima of 220 nm and 254 nm. 
 
Next, we analyzed N-PE-α-Me-PanAm by HPLC (see section 2.2.21.1 except these were not 
derivatized) using a Luna 5u C18(2) 100A 250 x 4.60 mm column with 50 mM phosphate buffer (pH 
6.8) and acetonitrile as eluents to determine whether this method would result in sufficient detection 
of N-PE-α-Me-PanAm at the absorption maxima determined. We injected 5 µM, 50 µM and 500 µM 
of N-PE-α-Me-PanAm to determine the differences in absorption at the various concentrations. At 
both wavelengths the peak for N-PE-α-Me-PanAm was visible at 50 min. As expected the baseline 
for the absorption at 254 nm was more stable than for the chromatogram at 220 nm (Figure 3.6 A 
and B), however the intensity of the absorbance at 254 nm was 2.5 times lower than at 220 nm. 
Since we were uncertain how much conversion to product we would be able to detect when using 
parasite lysate, we used 220 nm as wavelength for detection in further experiments. In addition, the 
differences in absorbance between 5 µM, 50 µM and 500 µM N-PE-α-Me-PanAm were also not very 
pronounced, therefore we also performed all future reactions using 5 µM of N-PE-α-Me-PanAm. 
 
Stellenbosch University  https://scholar.sun.ac.za
49 
 
Time (min)
0 10 20 30 40 50
A
b
s
o
rb
a
n
c
e
 (
m
A
U
)
-200
0
200
400
600
800
220 nm
 
Time (min)
0 10 20 30 40 50
A
b
s
o
rb
a
n
c
e
 (
m
A
U
)
0
50
100
150
200
250
300
254 nm
 
Figure 3.6: HPLC analysis of different concentrations of N-PE-α-Me-PanAm at a 
wavelength of (A) 220 nm and (B) 254 nm: 5 µM PanAm (in blue), 50 µM PanAm (in green), 
and 500 µM PanAm (in red). The N-PE-α-Me-PanAm peak eluted at ~50min. 
A 
B 
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3.2.2.1.2 Analysis of N-PE-α-Me-PanAm metabolism via UV absorbance 
N-PE-α-Me-PanAm was incubated with P. falciparum cell lysates (which should contain all the CoA 
biosynthetic enzymes) and three equivalents of ATP for 24 hours after which it was analyzed using 
HPLC while monitoring the separation at 220 nm (Figure 3.7). The same column was used as 
described above, however the eluents were changed to 10 mM ammonium acetate (pH 5.5) and 
methanol to improve separation and baseline stability, and the solvent gradient was adapted to allow 
for shorter analysis time (see section 2.2.21.2). Standards of N-PE-α-Me-PanAm and ATP were 
injected to allow for substrate identification. Although peaks were visible for both ATP and N-PE-α-
Me-PanAm, (Figure 3.7) neither compound eluted as one single peak. ATP eluted in three 
overlapping peaks between 2.1 and 2.65 min, while the N-PE-α-Me-PanAm standard contained four 
peaks between 10.5 and 16 min, with the major peak eluting at 13.6 min. Only two very small peaks 
not present in the standards were visible at 3.53 min and 9.86 min, suggesting that antimetabolites 
were not formed under these conditions. 
 
Since we do not know the specific concentration or activity of the CoA biosynthetic enzymes present 
in parasite lysate, the lack of product peaks could be due to very low turnover of substrate to product 
which might then fall under the detection limit of UV absorbance at 220 nm. We therefore explored 
the use of an alternative detection method. 
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Figure 3.7: UV chromatogram at 220 nm of N-PE-α-Me-PanAm incubated in the presence 
of parasite lysate and ATP for 24 hours. Peaks indicated in green were identified as ATP 
(between 2.15 min and 3.40 min) and in red represents PanAm (between 10.58 min and 
15.50 min) as compared to provided standards.  
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3.2.2.2 Analysis of N-PE-α-Me-PanAm metabolism via LCMS 
Since we needed to use a more sensitive method for the analysis of our reactions we reverted to 
detection with mass spectrometry (MS). To validate a liquid chromatography mass spectrometry 
(LCMS) method used in another study where other PanAm analogues were investigated in S. aureus 
[17], we determined if all the expected antimetabolites that can form are detected by this method. 
Standard reactions were set up with E. coli and S. aureus CoA biosynthetic enzymes that were 
obtained by recombinant expression in E. coli. Consequently, SaPanK, EcPPAT and EcDPCK were 
incubated with 5 mM N-PE-α-Me-PanAm and 10 mM ATP for 24 hours before the reaction was 
stopped by heat precipitation of the proteins and the samples submitted for LCMS analysis (ESI 
positive and negative mode) at CAF (Figure 3.8). 
Time (min)
0 5 10 15 20
In
te
n
s
it
y 
(c
p
s
)
0
5e+4
1e+5
2e+5
2e+5
220nm
 
Figure 3.8: LCMS chromatogram (TOF-MS, ESI positive, BPI) N-PE-α-Me-PanAm 
incubated with SaPanK, EcPPAT and EcDPCK and ATP. The peaks were identified as (1) 
ATP and ADP at 1.68 minutes (mass found: 508.00 and 428.04, mass expected: 507.99 
and 428.03), (2) 4’-phospho-N-PE-α-Me-PanAm at 12.13 minutes (mass found: 417.18, 
mass expected: 417.17), (3) N-PE-α-Me-PanAm at 12.99 minutes (mass found: 337.21, 
mass expected: 337.21), (4) N-PE-α-Me-dephosphoCoA at 10.84 minutes (mass found: 
746.23, mass expected: 746.22), and (5) N-PE-α-Me-CoA at 8.96 minutes (mass found: 
826.20, mass expected: 826.19).  Peaks after 12.99 minutes were not identified and are 
unknown. 
 
All the antimetabolites were detected via LCMS (positive mode) with ATP and ADP co-eluting at 1.68 
min, N-PE-α-Me-CoA at 8.95 min, N-PE-α-Me-dephosphoCoA at 10.84 min, 4’-phospho-N-PE-α-
Me-PanAm eluting at 12.13 min and finally the substrate N-PE-α-Me-PanAm at 12.99 min. As a 
result, we were able to successfully validate the LCMS method for separation and detection of the 
PanAm antimetabolites in samples.  
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3.2.2.2.1 N-PE-α-Me-PanAm conversion in P. falciparum lysate 
Since we had a confirmed method that could detect the CoA antimetabolite intermediates formed by 
the CoA biosynthetic enzymes, and which separates the antimetabolite intermediates well, this 
method was used to determine whether the CoA biosynthetic enzymes in lysate isolated from P. 
falciparum are able to convert the PanAms to their relevant CoA antimetabolites like the bacterial (S. 
aureus and E. coli) enzymes were found to do. For this, parasite lysates were incubated with N-PE-
α-Me-PanAm for 24 hours and the resulting products submitted for analysis by LCMS (ESI positive 
and negative mode). 
 
Although in the previous section the antimetabolites were detected in ESI positive mode, no peaks 
were identified. However, after evaluation of chromatogram in ESI negative mode, co-elution of ATP 
and ADP was detected at 2.03 min with a peak corresponding to the substrate N-PE-α-Me-PanAm 
observed at 12.68 min (Figure 3.9). The only biotransformed metabolite observed was 4’-phospho-
N-PE-α-Me-PanAm, which eluted at 12.68 min although in a much smaller amount in comparison to 
N-PE-α-Me-PanAm. No PE-α-Me-dephosphoCoA (expected at ~9 min) or PE-α-Me-dephosphoCoA 
(expected at ~11 min) were detected.  This could mean that too little of these antimetabolites are 
formed to allow for detection by LCMS, or that these antimetabolites are not formed by the P. 
falciparum enzymes implying that PPAT is inactive. Alternatively PPAT does not accept 4’-phospho-
N-PE-α-Me-PanAm as substrate.  
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Figure 3.9: LCMS chromatogram (TOF-MS, ESI negative, TIC) of N-PE-α-Me-PanAm 
incubated with P. falciparum cell lysates for 24 hours. The peaks were identified as (1) 
ATP and ADP at 2.03 minutes (mass found: 506 and 426, mass expected: 505.99 and 
426.03), (2) 4’-phospho-N-PE-α-Me-PanAm at 12.68 minutes (mass found: 415, mass 
expected: 415.17), and (3) N-PE-α-Me-PanAm at 13.47 minutes (mass found: 335, mass 
expected: 335.21).  
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The finding that 4’-phospho-N-PE-α-Me-PanAm is biosynthesized by PfPanK is not surprising since 
several other studies have shown that PfPanK in parasite lysate is active [1, 7, 12]. However, no 
information is known about the activity of PPAT and DPCK, since no studies have ever investigated 
the activity of these two enzymes in lysates prepared from P. falciparum. In order to confirm that we 
have active PPAT and DPCK present in the prepared lysate, an alternative possible substrate of 
PanK (pantetheine) and the substrate of DPCK (dephospho-CoA) was incubated in the presence of 
ATP and P. falciparum lysate, and subjected to LCMS analysis (ESI positive and negative mode). 
These reactions would result in the formation of dephospho-CoA if PPAT is active, or CoA if DPCK 
is active. However, none of the CoA metabolites could be detected by this method, indicating that 
either the antimetabolites are present in such miniscule concentrations that the method of detection 
is not sensitive enough, or that the P. falciparum PPAT and/or DPCK are inactive in the lysates.  
 
An alternative analysis method in our laboratory allows for the utilization of the terminal thiol present 
in the natural metabolites occurring in the CoA salvage pathway (Figure 1.8) to derivatize these 
compounds with CPM, a thiol-reactive compound that has weak fluorescent properties until it reacts 
with thiols (Figure 3.10). This allows detection by fluorescence when HPLC analysis is performed 
[13]. We therefore reverted to this method to determine if the PPAT and DPCK present in parasite 
lysates are active, since fluorescent detection will increase sensitivity of detection and possible 
problems with ionization via MS could be excluded. P. falciparum parasite lysate was incubated with 
the natural substrates pantetheine (5 mM) and dephospho-CoA (5 mM) for 24 hours, after which the 
samples were derivatized with CPM and analyzed via HPLC with fluorescent detection at an 
excitation and emission of 387 nm and 465 nm, respectively. 
 
 
Figure 3.10: The chemistry of CPM labeling of thiolated compounds. CPM is a thiol-
reactive compound that has weak fluorescent properties until it reacts with  free thiols. 
Stellenbosch University  https://scholar.sun.ac.za
54 
 
From the HPLC analysis (Figure 3.11A), we see that 4’-phosphopantetheine (retention time of 4.27 
min) is produced by PfPanK from pantetheine, however no dephospho-CoA (retention time 4.92 min) 
or CoA (retention time of 4.15 min) is produced (expected product elution times were confirmed by 
spiking samples with known samples of 4’-phosphopantetheine, dephospho-CoA and CoA). This 
indicates that PPAT in P. falciparum lysate is inactive.  Interestingly, analysis of the reaction mixture 
with dephospho-CoA as substrate indeed showed the formation of CoA, illustrating that PfDPCK is 
active. We next investigated if the Tris buffer used in the reaction was the cause for the poor PPAT 
activity, and therefore repeated both reactions with pantetheine and dephopsho-CoA in HEPES 
buffer at pH 8. The same results were obtained as for the reactions performed in Tris buffer with 4’-
phosphopantetheine formation visible from pantetheine, and CoA from dephospo-CoA. However, no 
PPAT activity was observed (data not shown). 
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Figure 3.11 Fluorescence chromatogram (with excitation and emission wavelengths at 
387 nm and 465 nm respectively) of HPLC injected cell lysates incubated with (A) 
pantetheine and lysates stored in Tris buffer, and (B) Dephospho-CoA with lysates stored 
in Tris buffer, for 18-24 hours. Peaks are identified as (1) TCEP, (2) 4’ -
phosphopantetheine, (3) pantetheine, (4) Dephospho-CoA, (5) CoA and (6) cysteine. 
Although no peak is visible on the chromatogram, CoA was present but omitted from the 
chromatogram due to a system overload at 4.15 min (indicated by blue line) because of 
a high metabolite concentration.  
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3.2.2.2.2 Analysis of N-PE-α-Me-PanAm conversion in P. falciparum cultures in vitro. 
To further investigate whether P. falciparum metabolizes N-PE-α-Me-PanAm downstream from 
PfPanK we investigated the fate of this compound in parasite cultures in vitro. Cultures were treated 
with a non-lethal dose of N-PE-α-Me-PanAm (i.e. a concentration equivalent to the IC50  of 52 nM ± 
6 nM determined previously [6]) for 24 hours, after which the parasites were isolated, lysed, proteins 
precipitated and removed, and the cellular contents submitted for LCMS analysis. Although 
pantetheine, 4’-phosphopantetheine and a very small amount of CoA were detected as evidenced 
by the peaks at 15.85 minutes, 12.99 and 15.18 minutes respectively (Figure 3.12), dephospho-CoA 
was not detected. In addition, no N-PE-α-Me-PanAm or any of its corresponding antimetabolite 
intermediates were detected by LCMS in either ESI positive or negative modes. 
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Figure 3.12: LCMS chromatogram (TOF-MS, ESI positive, BPI) of N-PE-α-Me-PanAm 
incubated with P. falciparum whole cells in culture for 24 hours. The peaks were 
identified as (1) 4’-phospho-pantetheine at 12.99 minutes (mass found: 359, mass 
expected: 359.10), (2) CoA at 15.18 minutes (mass found: 767, mass expected: 767.12), 
and (3) Pantetheine at 15.85 minutes (mass found: 278, mass expected: 279.13). Non-
labelled peaks were not identified and are unknown.  
 
3.2.3 Synthesis and evaluation of the effect of a PanK inhibitor that is 
not a pantothenate analogue on P. falciparum CoA biosynthesis.  
To confirm that PanAms do not inhibit PfPanK, but are rather metabolized by this enzyme to affect 
targets downstream in the pathway, we wanted to prepare a PanK inhibitor that is not an analogue 
of the natural substrate of PanKs, pantothenate. Recently, studies by Sharma et. al have shown that 
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human PanK can be inhibited by tricyclic methylthiophenyl propanamides (TMPs), which are not 
structurally related to pantothenate [18]. TMPs have been found to bind to the ATP-PanK complex 
to assert their inhibitory effect, and it was shown that increasing concentrations of these TMPs cause 
a decrease in CoA levels [18].  
Our aim was therefore to synthesize a TMP analogue and test it on P. falciparum to see if it has any 
inhibitory effect on PfPanK and parasite proliferation. If so, it should inhibit by lowering CoA levels 
since it shuts down CoA biosynthesis at the first enzyme. This could then be used as a possible tool 
to compare to PanAms as inhibitors in order to determine if PanAms lower CoA levels in a different 
way—the difference being that the TMP analogue cannot act as alternative substrates and the 
PanAms can, since they are pantothenate analogues.  
3.2.3.1 Synthesis and purification of TMP  
Using the methods published by Sharma et. al [18], we set out to synthesize TMP in four steps 
starting from 2-chloro-3-pyrimadinecarbonitrile (Figure 3.13A). The syntheses of compounds 1 and 
2 were performed according to the published method, except that instead of using a microwave-
assisted procedure, the reaction mixtures were refluxed overnight. The reaction for compound 1 was 
successful and we obtained the product as a yellow precipitate in a yield of 40%. The structure of 
the product was confirmed by 1H NMR spectroscopy, showing a purity of >95%. Compound 2 was 
prepared from compound 1 by refluxing overnight under nitrogen in ethanol in the presence of methyl 
4-acetyl-5-oxohexanoate. This resulted in a clear orange mixture that was concentrated in vacuo to 
obtain a yellow product without further purification in a yield of 97%. The structure of the product was 
confirmed by 1H NMR spectroscopy, which showed a purity of >95%. To obtain compound 3, 
hydrolysis of the methyl ester was performed with 1 M NaOH in THF overnight. After work-up the 
product was obtained as a white powder in a yield of >99%. The structure of the product was 
confirmed with 1H NMR and its purity estimated at >95%.  
 
Although the first three synthetic transformations were performed successfully, significant problems 
were encountered in executing the last step. Since our attempts to reproduce published methods 
were not always successful, we also used alternative methods (Figure 3.13B) in the attempt to 
successfully synthesize the PanK inhibitor, TMP. Various attempts were made to couple the 
carboxylic acid (compound 3) with 3-(methylthio)alanine with limited success; the attempts are 
summarized in Table 3.1. The first attempt involved using HBTU as activating agent as per published 
method [19]. However, the procedure calls for the purification of the reaction mixture via preparative 
HPLC on a reversed phase column, and since we did not have access to such a system, we therefore 
had to investigate alternative means for purification. Flash column chromatography using silica and 
methanol/dichloromethane (5-10%) as eluent was used to attempt purification. Although purified 
product was recovered from the column and identified via 1H NMR (Figure 3.15A), too little (<2 mg) 
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was obtained for any further use. As an alternative the reaction was attempted a second time with 
an added work-up step before purification; however this attempt was unsuccessful.  
 
Alternative activation strategies were attempted to allow more product formation in order to simplify 
purification. One of these attempts involved the use of EDC in the presence of HOBt as activation 
reagent of the carboxylic acid, however without success.  Another route attempted was amidation 
by means of B(OCH2CF3)3, which was prepared from B2O3 and 2,2,2-trifluoroethanol. After 
completion of the reaction, the resulting reaction mixture was diluted with ethyl acetate and water 
and stirred with Amberlyst A-26(OH) (anion exchanger), Amberlyst 15 (cation exchanger) and 
Amberlite IRA743 resins (chelator). These resins should remove all impurities except the expected 
product, which is a neutral compound, in order to simplify purification. Unfortunately this procedure 
also failed to produce the final product. 
  
 
 
Figure 3.13: (A) Original synthesis of TMP as set out by Sharma et. al [18], and (B) a 
scheme of the alternative last step, whereby compound 3 is first converted to the acid 
chloride (compound 5) before the attachment of the amide to form TMP or compounds 6 -
8. 
A 
B 
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Finally, an alternative strategy was attempted by preparing the acid chloride in catalytic amounts of 
DMF, followed by the addition of 3-(methylthio)aniline dissolved in picoline (Figure 3.13B). We also 
investigate three other amines (3-fluoroaniline, 3-(trifluoromethyl)aniline and  4’-aminoacetanilide) to 
determine if the problem encountered in the coupling could be due to the structure of the amine; 
these alternative amines were used in the published method for the production of other TMP 
analogues that also gave good inhibition profiles. The reactions were followed by TLC in 10% 
methanol/dichloromethane. The reaction with 3-fluoroaniline seemed the most promising with a UV 
active spot at Rf ~0.21 as possible product. This reaction was purified by means of a silica plug with 
5%-10% methanol/dichloromethane, however the product could unfortunately not be isolated (Figure 
3.15B). 
 
 Table 3.1: Summary of the methods investigated for TMP synthesis.  
Activation group Amine Product formation Purification 
HBTU 3-(methylthio)alinine Yes Partially successful 
EDC 3-(methylthio)alinine Yes Partially successful 
B(OCH2CF3)3 3-(methylthio)alinine No Not purified 
-Cl 3-(methylthio)alinine No Not purified 
-Cl 3-(trifluoromethyl)aniline Yes No 
-Cl 3-fluoroaniline Yes Not purified 
-Cl 4’-aminoacetanilide No Not purified 
 
 
 
 
 
 
 
 
 
 
Figure 3.14: TLCs at (A) 254 nm (UV) and (B) 336 nm (fluorescence) of all 4 compounds 
synthesized in amidation reaction with the acid chloride. TLCs were run in 10% 
methanol/DCM. The spots were as follows (S) compound 4, compound 4 and all added 
components before the reaction was stirred, with 3-(methylthio)aniline (S1),  3-
fluoroaniline (S2), 3-(trifluoromethyl)aniline (S3), and  4’-aminoacetanilide (S4) as the 
added amines, and the products after the reactions with 3-(methylthio)aniline (P1),  3-
fluoroaniline (P2), 3-(trifluoromethyl)aniline (P3), and  4’-aminoacetanilide (P4) as the 
added amines. The product we are aiming to synthesize is both UV active and 
fluorescent. The black box indicates the reaction that seemed to have best product 
formation and is the reaction that was chosen for further analysis.  
S    S1   P2   S2    P2   S3   P3    S4   P4 S    S1   P2   S2    P2   S3   P3    S4   P4 
A B 
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Figure 3.15: 1H NMR analysis of (A) TMP synthesized by HBTU coupling of the amine to 
the carboxylic acid purified on a silica column (5% methanol/DCM, 20% methanol/DCM), 
dissolved in DMSO (1H NMR is consistent with literature data [8]) , and (B) the partially 
purified product formed from the amidation reaction using acid chloride derivative and 
purification by silica plug using 5%-10% methanol/DCM, dissolved in deuterium oxide.  
Unassigned peaks were either impurities or unknowns.  
B 
A 
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3.2.3.2 TMP as inhibitor of PfPanK in parasite lysate and parasite growth   
The last two objectives of this study (to test TMP as inhibitor of PanK-mediated phosphorylation of 
pantothenate and as antiplasmodial against P. falciparum parasites in culture) were dependent on 
the successful synthesis of TMP. Since we were unable to purify enough material to perform these 
experiments these objectives will be addressed in future work.  
 
3.3 Discussion 
3.3.1 Minimum extracellular pantothenate needed for parasite survival 
A study of the nutrient requirements of malaria parasites can be complex and usually requires the 
preparation of custom-made culture media (for the purpose of this study, RPMI-1640 media without 
pantothenate present), and considering the complexity of the medium, there is high chance for error. 
Pan-free culture medium was prepared in-house, however parasites were not supported by this 
medium. This might be due to the medium either lacking an essential component for parasite growth 
or some of the components sourced where not of sufficient quality for cell culture. 
 
To eliminate error with media preparation, we sourced custom made Pan-free RPMI-1640 media 
commercially and repeated control experiments to determine if parasite growth can be sustained in 
this media with the addition of pantothenate compared to when pantothenate is not present. 
Surprisingly, the P. falciparum parasites were surviving in the Pan-free media up to ~92% after 4 
days in a microtiter plate (96-well). In a follow-up experiment, small-scale cultures were cultured in 
a Pan-free environment with culture media containing no pantothenate being replaced daily. In these 
experiments parasites were surviving for 7 days with pantothenate being absent in their otherwise 
nutrient-rich environment. This finding is in contrast to what was found by other groups that have 
shown that P. falciparum 3D7 parasites can only survive in a Pan-free environment for 3-4 days [1, 
10]. In these studies either manual counting of parasitemia by light microscopy was used [10] or a 
radiolabeled assay that measures the incorporation of [3H]hypoxanthine into viable parasites [1]. In 
this thesis we described three methods used to determine parasite survival of which one was also 
manual counting of parasitemia by microscopy in addition to a Malstat and SYBR Safe assay that 
has not been used previously for this purpose. 
 
The first method (manual counting) show an increase in parasitemia from 1% (similarly to what was 
used by Mamoun et al. and Saliba et. al to initiate the experiment [10]) to ~5% at days 2 and 3, after 
which parasite growth decreases to 1%. This is in line with what was found by Mamoun et al. who 
showed that parasitemia decreased after the first 3 days. However, no parasite growth was visible 
after 3 days in their study whereas we still observed residual parasite growth of ~0.5% up until day 
7. Manual counting of parasites is prone to human error due to parasites in ring phase, as well as 
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those deprived of pantothenate, being smaller and therefore more difficult to see under light 
microscopy. This method is also time consuming and impractical for high numbers of cultures. We 
therefore reverted to other assays, such as the SYBR Safe and Malstat assays, that are more 
sensitive. 
 
The second method used was the SYBR Safe assay, where SYBR Safe (a nucleic acid stain) binds 
to viable parasite DNA (erythrocytes have no DNA) and the resulting DNA-dye-complex allows for 
fluorescent determination of parasite survival [20]. Alternatively we also used the Malstat assay, also 
known as an LDH assay. Here Malstat reagent, NBT/PES solution and cultures initiate a lactate 
dehydrogenase reaction (measured colourmetrically) as NBT is reduced [21]. Viable parasites will 
still produce lactate that will allow this colour change to measure parasite growth. Both erythrocytes 
and P. falciparum produce lactate, therefore there will be a slight colourometric change even when 
studying uninfected erythrocytes, however the amount of lactate contributed by erythrocytes is 
minimal when compared to the amounts produced by the parasites. In both these assays parasite 
growth increased for 4 days after which a dramatic decrease in parasite growth was observed. 
However, residual amount of parasites still survived up until day 7 similarly to what was observed 
using manual counting.  
 
The majority of P. falciparum parasites do not survive more than 96 hours without pantothenate 
present, which correlates with findings by Saliba et. al who used a hypoxanthine assay to determine 
parasite survival in the absence of pantothenate [1] by measuring the level of radioactivity of the [3H]-
hypoxanthine incorporated into nucleic acids of the parasites when they proliferate. However in this 
study, similar to that of Mamoun et al., no residual growth was visible [1, 10]. The observed 
differences between parasite survival in this study compared to published data can be rationalized 
in various ways. First, it is possible that the Plasmodium strain has mutated, which has been seen 
to happen after many rounds of sorbitol synchronizations [22], however this is unlikely to change the 
capability of the parasites to survive without pantothenate since so many biological processes rely 
on CoA. Alternatively, there could be another source of pantothenate providing the parasites with 
the vitamin for survival. This seems like a more likely explanation since P. falciparum has no 
metabolic pathway to synthesize pantothenate de novo and thus has to gain the pantothenate from 
its environment. 
 
Possible alternative sources of pantothenate could be from culture contamination by other 
organisms. Since no contamination of cultures was visible under light microscopy, we tested cultures 
for possible Mycoplasma contamination. PCR detection of Mycoplasma confirmed that the cultures 
were indeed infected. Mycoplasma infection of cultures can have varying effects on cell cultures, 
and the effects varying in severity—all dependent on the Mycoplasma species, the type of culture 
that is infected, and the culturing conditions [23]. Mycoplasma infections can hinder most if not all 
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facets of cell cultures, including cellular metabolism [11], thus although Mycoplasmas do not kill or 
noticeably suppress the growth of the Plasmodium parasites, they can interfere with the parasites’ 
metabolism or in this case be a source of small amounts of pantothenate that can sustain parasites 
survival albeit in residual amounts. This therefore highlights the need to remove these organisms 
from cell cultures to accurately study the parasites’ metabolism of pantothenate and its survival in a 
Pan-free environment.  
 
Even though cultures were treated for the removal of Mycoplasma in order to confirm that this 
organism are indeed the source of residual pantothenate, these experiments were unfortunately not 
successful and due to time constraints were not repeated. As a results we could also not determine 
the minimum amount of pantothenate needed for parasite survival and therefore these experiments 
will be addressed in future work.  
 
3.3.2 Metabolism of PanAms by the CoA biosynthetic enzymes of P. 
falciparum  
It is known that in bacteria PanAms are converted to antimetabolites to exert their inhibitory effect 
[24]. To determine whether N-PE-α-Me-PanAm has a similar mode of action in P. falciparum we 
investigated whether this compound can be converted to the corresponding CoA antimetabolites by 
the CoA biosynthetic enzymes present in P. falciparum parasites. We first confirmed which analytical 
technique would allow sufficient sensitivity to allow the identification of substrate and antimetabolites. 
Two approaches were considered where either parasite lysates or cell cultures were used to 
determine the conversion of N-PE-α-Me-PanAm to its corresponding antimetabolites. However, 
since we are not able to perform this experiment using purified proteins or high cell numbers when 
using cell cultures (as is the case when working with bacteria), we needed to ascertain that our 
method of detection is reliable for metabolite identification. After various experiments looking at the 
UV absorbance of N-PE-α-Me-PanAm we determined that the sensitivity of this method will not be 
sufficient to detect product formation. As an alternative we validated a different method utilizing 
LCMS that was previously used for PanAm metabolism studies in S. aureus [17]. The LCMS method 
proved to have adequate sensitivity to locate the antimetabolites when incubating N-PE-α-Me-
PanAm with recombinant CoA biosynthesis proteins from E. coli and S. aureus. In fact, we 
successfully showed for the first time that N-PE-α-Me-PanAm can be converted by enzymes from 
the CoA biosynthesis pathway to the corresponding CoA antimetabolites, albeit from bacteria. This 
gave as the tools to explore if the same process can take place in P. falciparum.  
Consequently, the same LCMS method was used to analyse N-PE-α-Me-PanAm incubated with P. 
falciparum cell lysate containing CoA biosynthesis proteins. The formation of 4’-phospho-N-PE-α-
Me-PanAm indicated that PfPanK is active in parasite lysate, as is known from previous studies [1, 
25, 26, 27]. In addition we also demonstrated for the first time that this specific PanAm can act as 
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substrate for PfPanK which aligns with recent studies that found that PfPanK is the gateway for 
PanAm mediated inhibition of P. falciparum [26]. The PanAm therefore has to be metabolically 
activated by this enzyme to exert their inhibitory effect downstream in the pathway. However the fate 
of the molecule downstream in the pathway is still unknown since no corresponding dephospho-CoA 
and CoA antimetabolites were observed. This could be due to several reasons. First, it might be that 
the metabolites fall under the limit of detection of the method, especially since very low amounts of 
4’-phospho-N-PE-α-Me-PanAm are observed. Secondly, PPAT and DPCK might not be active in 
parasite lysate.  
 
To further investigate the activity of PPAT and DPCK we exposed these proteins to the natural 
substrate pantetheine and dephospho-CoA. Surprisingly, no activity was observed for any proteins 
from the CoA pathway (not even PfPanK that showed activity previously). CoA metabolites have 
very poor ionization capability and can have varying results when analyzing by LC-MS. We therefore 
reverted to a third method of detection since we were investigating the natural metabolites. This 
allowed the use of CPM derivatization of the terminal thiol to detect these compounds via 
fluorescence. No activity was found for PPAT (even performing the experiment in two different 
buffers); however, we found that DPCK is active in parasite lysate prepared in either Tris or HEPES 
buffer. This is the first experiment, to our knowledge, that successfully demonstrates DPCK activity 
in parasite lysate prepared from isolated parasites. This is especially important since DPCK is 
localized to the apicoplast of the parasite and no information regarding the status of the organelle is 
known in lysates. Whether the apicoplast is lysed or still intact after manual lysis is still unknown, 
however we have demonstrated that DPCK present in this organelle is functional once the parasite 
is isolated and lysed.  
 
The fact that PPAT was inactive supports no antimetabolite formation in the presence of 4’-phospho-
N-PE-α-Me-PanAm downstream from PfPanK. However, PPAT might require different reaction 
conditions than those used in this study. The formation of the antimetabolites can therefore not be 
excluded. Alternatively, N-PE-α-Me-PanAm was incubated in cell culture and analyzed after 24 
hours, however no antimetabolites (not even 4’-phospho-N-PE-α-Me-PanAm) could be detected. In 
this case the amount of antimetabolite formation is most likely under the limit of detection and 
probably requires a large amount of cell cultures to isolate enough parasites for analysis. This is a 
costly process and also consumes a lot of substrate that would need to be synthesized in-house. 
3.3.3 Synthesis and evaluation of the effect of a PanK inhibitor on P. 
falciparum CoA biosynthesis that is not a pantothenate analogue.  
To support the fact that N-PE-α-Me-PanAm exerts its effect downstream in the CoA biosynthesis 
pathway, we considered comparing the inhibitory effect of this pantothenate analogue to a compound 
that is a PanK inhibitors but is structurally not related to pantothenate. Recently it has been show 
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that TMP is an inhibitor of human PanK3 and exerts its inhibitory effect by lowering CoA levels. In 
order to use this compound for comparison to PanAms we first had to synthesize the TMP and 
determine if it has antiplasmodial properties.  
 
The synthesis of TMP was performed according to published work [18]. While compounds 1-3 were 
synthesized and purified in good to excellent yields (40%, 97% and >99% respectively), the final 
product proved to be difficult to obtain. This is mainly due to the chemical properties of the final 
product that makes purification of the final product cumbersome, regardless of which method was 
used to prepare it. This led to major loss of product where purification methods were not sufficient to 
purify compound 5, thus yielding only a partially purified product. The original synthesis of this 
compound described the use of preparative HPLC for the purification of TMP. Unfortunately we did 
not have preparative HPLC to our disposal and had to revert to alternative purification methods like 
silica purification or purification by cation and anion exchange. Silica purification was not successful 
and proved to decrease the stability of the product in non-polar solvents. Even though cation and 
anion exchange purification strategies where also employed we had no success. The reason for this 
is unclear. 
 
However we were successful in purifying trace amounts of TMP to confirm product formation. We 
were able to synthesize a small amounts of the partially purified compound (Figure 3.16B), however 
due to impurities we did not feel confident in testing this product further on P. falciparum. As a result 
we did not have sufficient amounts of product to test it as a PanK inhibitor on P. falciparum.  
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Chapter 4: Conclusion and Future Work 
 
4. 1 Conclusion 
4.1.1 Establishing the minimum extracellular pantothenate needed for parasite 
survival 
CoA plays an important role in central metabolism, and it is known that the CoA pathway is crucial 
for the survival of Plasmodium [1]. Since CoA cannot be taken up by the parasite and pantothenate 
is the substrate for the CoA biosynthesis pathway, previous research has focused much attention on 
pantothenate analogues as novel antimalarials. Analogues such as PanAms are known to inhibit P. 
falciparum parasite proliferation, however the PanAms’ mode of action is unknown [2]. However, the 
addition of extracellular pantothenate antagonizes the effect of PanAms on P. falciparum proliferation 
and thus PanAms are thought to interfere with pantothenate metabolism [1]. A key question to 
answer when setting out to establish what the effect of PanAms on pantothenate utilization is, is 
what the critical amount of CoA is needed for P. falciparum survival. This is because one of the 
possible modes of action would be the lowering of CoA levels; it is therefore important to know 
whether PanAm treatment causes CoA levels to fall to critical levels. Another way to address this is 
to establish how long the parasites can survive when transferred to medium without pantothenate, 
as this would give an indication of their ability to survive only on the pantothenate-derived metabolites 
that are present in the cells at the time of transfer. We first determined that the parasites can survive 
without pantothenate for 4 days, after which residual amounts of parasites survive for up to 8 days. 
The longer-than-expected survival times were not in line with the results of previous studies. 
Subsequent investigations found that the parasite cultures used in these tests were infected with 
Mycoplasma spp, and we therefore concluded that the presence of Mycoplasma in the cultures 
extended the survival of the parasites in Pan-free media. There are two possible ways in which we 
hypothesize this can occur: either by alteration of the parasites’ metabolism, leading to a lower 
demand for pantothenate, or by acting as a source of pantothenate for P. falciparum parasites. 
However these hypotheses will have to be tested in Mycoplasma-free cultures. The experiments that 
were executed to determine the minimum amount of pantothenate required for P. falciparum survival 
was consequently not conclusive due to the uncertainty about the effect of the Mycoplasma 
contamination on the cultures. 
 
4.1.2 Metabolism of PanAms by the CoA biosynthetic enzymes of P. falciparum 
While we know that PanAms show antiplasmodial activity and that their mode of action is connected 
to the CoA biosynthetic pathway, we wanted to determine whether PanAms target one of the 
enzymes in the CoA biosynthesis pathway directly, or whether they are converted by the CoA 
biosynthetic enzymes to CoA antimetabolites that affect processes dependent on CoA. After 
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validating HPLC and LCMS methods for the detection of the CoA metabolites and the PanAm-related 
CoA antimetabolites respectively, we determined that N-PE-α-Me-PanAm is converted to 4’-
phospho-N-PE-α-Me-PanAm by PfPanK in vitro. However, the results indicated that PfPPAT is 
inactive in cell lysates, as the subsequent biosynthetic intermediates were not detected. This 
inactivity could be due to the enzymes being unstable in the lysis buffer, or because we do not fully 
understand its requirements for activity.   
However, we have shown (for the first time) that DPCK is active in parasite lysate prepared from 
isolated P. falciparum parasites, which opens up new avenues for studies on this enzyme as a 
possible antiplasmodial target.  
 
4.1.3 Synthesis and evaluation of the effect of a PanK inhibitor that is not a 
pantothenate analogue on P. falciparum CoA biosynthesis.  
From a study done by Sharma et. al [3], TMP was shown to inhibit human PanK3 by binding to the 
ATP-PanK complex,  which leads to a decrease in CoA levels. It was thus hypothesized that if TMP 
inhibits PfPanK, it can be used as a tool to show that PanAms (which are pantothenate analogues) 
have a different mode of action than TMP (which is not a pantothenate analogue) and do not exert 
their inhibitory effect on PfPanK. While we were successful in synthesizing the immediate precursor 
to TMP, we encountered several stumbling blocks in the last step of the synthesis. A significant 
problem was purification of the compound, which, due to its polarity characteristics, was not 
amenable to purification by normal phase chromatography. As a result we were unable to test or 
compare the inhibitory effect of TMP to N-PE-α-Me-PanAm. 
 
4.2 Future Work 
4.2.1 Establishing the minimum extracellular pantothenate needed for parasite 
survival 
Due to the discovery of the Mycoplasma infection of the Plasmodium cultures at a late stage in this 
study, we were not able to repeat the appropriate experiments with cultures that were known to be 
Mycoplasma-free. I therefore propose that the following experiments are repeated for better and 
more accurate results: (1) the parasite survival in Pan-free media using Mycoplasma free cultures; 
this is to establish whether Mycoplasma indeed extends the parasites life-span without extracellular 
pantothenate added to culture media. (2) determining the minimum amount of extracellular 
pantothenate necessary for P. falciparum survival, since in this study we were unable to find what 
the lowest concentration of pantothenate is necessary to support parasite proliferation.  
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4.2.2 The critical amount of CoA for P. falciparum survival 
Once the minimum concentration of extracellular pantothenate that sustains P. falciparum survival 
is determined, it will be important to establish how this correlates with the intracellular CoA 
concentration. Does the intracellular CoA concentration track the extracellular pantothenate 
concentration, or is the internal CoA concentration maintained at a certain level regardless of what 
it can obtain from outside sources? To determine this, cultures will be treated at the different levels 
of pantothenate and then analyzed by the already validated HPLC method (using CPM derivatization 
for fluorescence detection of CoA metabolites) to determine the CoA levels at different pantothenate 
concentrations. This will give an indication of the critical amount of CoA needed for parasite survival. 
We will also investigate whether PanAm-treated cultures display the same levels of CoA, therefore 
whether PanAm-treatment decreases the amount of CoA to levels that are insufficient for parasite 
survival.  
 
4.2.3 Investigate the inactivity of PfPPAT in vitro 
Due to the fact that PfPPAT was inactive in our in vitro experiments, the requirements of the enzyme 
in lysate should be revisited. Little information is known regarding this enzyme in P. falciparum even 
though a putative PPAT-encoding gene has been identified in the P. falciparum genome. However, 
this gene encodes a protein that does not show a high level of sequence homology to other 
eukaryotic PPAT enzymes, which could suggest that the parasite enzyme’s mechanism is different 
from that characterized for those enzymes. The enzyme’s need for specific cofactors and metal ions 
has to be investigated (Figure 4.1). Once it has been established what the requirements of the 
enzyme for activity is in lysate, parasites lysates in the presence of ATP and the required cofactors 
can be incubated with N-PE-α-Me-PanAm to establish if this PanAm is being metabolized 
downstream from PfPanK.  
 
Figure 4.1: Scheme representing PfPPATs possible need for alternative cofactors and metal ions. Not 
much is known about PPAT and thus it needs to be investigated.  
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4.2.4 TMP as potential antiplasmodial 
Since TMP could not be purified in this project, the last two objectives of the project could not be 
completed. If TMP could be successfully synthesized and purified (e.g. by preparative HPLC, which 
was not available in this study), TMP can be confirmed as a P. falciparum PanK inhibitor. As a 
positive control, TMP will be tested on human PanK3, after which it will be tested on PfPanK present 
in parasite lysates, using the same discontinuous radioactive assay that has been developed for 
tracking PanK activity in impure samples. This assay is a high-throughput method of monitoring the 
phosphorylation of small molecules, such as [14C]pantothenate to [14C]4’-phosphopantothenate by 
PanK [4]. TMP can then also be tested as inhibitor of P. falciparum parasite growth in culture to 
determine its IC50 value. TMP activity in P. falciparum can then be compared to that of N-PE-α-Me-
PanAm as an additional tool in our attempt to elucidate the PanAms mode of action in parasites. 
 
4.2.5 Attempt to elucidate the differences in N-PE-α-Me-PanAms enantiomer 
interactions 
Currently, the most potent PanAm in our library is N-PE-α-Me-PanAm, with an IC50 of 20 ± 3 nM. 
However this compound is currently synthesized as the diasteriomeric mixture (Figure 4.2). Other 
members in our laboratory have recently been successful in the synthesis of the (R)- and (S)-epimers 
of this compound, which would allow us to establish whether the epimers are equally resistant to 
vanin pantetheinase degradation, and/or show equal antiplasmodial activity. Both compounds 
should therefore be tested for their susceptibility to vanin degradation to determine if there are any 
differences in their sensitivity towards pantetheinase-mediated breakdown. In addition, they should 
be tested for their ability to inhibit P. falciparum proliferation to determine if there is a difference in 
their antiplasmodial activity. Not only may this point to an improved potency compared to the parent 
compound (since it is possible that in the diastereomeric mixture, one of the epimers is less active), 
but may also shed light on the characteristics of the molecular target of this particular PanAm. 
 
Figure 4.2: Chemical structures of the N-PE-α-Me-PanAm diastereomeric mixture as well as the (R)- 
and (S)-epimers. The portion in the grey blocks highlights the methyl group and its position and 
stereochemistry in the molecule. 
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4.3 Final Remark 
Taken together, the scope of the work still to be done on this project illustrates the relevance of the 
groundwork described in this thesis. Ultimately the elucidation of the mode of action of the PanAms 
will not only bring us one step closer to developing these compounds as clinically relevant 
antimalarials but may also provide us new information on the biology of the parasite. 
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